@article {pmid41386679,
year = {2025},
author = {Hamel, LP},
title = {Nicotiana benthamiana's Responses to Agroinfiltration, a Treasure Grove of New Avenues to Improve Protein Yields in Plant Molecular Farming.},
journal = {Plant biotechnology journal},
volume = {},
number = {},
pages = {},
doi = {10.1111/pbi.70460},
pmid = {41386679},
issn = {1467-7652},
abstract = {Transient expression of recombinant proteins in leaves of Nicotiana benthamiana is routinely employed for both basic research and manufacturing of biopharmaceutical products in plants. Relying on disarmed strains of the bacterial plant pathogen Agrobacterium tumefaciens as a transgene vector, this safe, cost-effective and easily scalable 'plant molecular farming' approach offers a reliable alternative to classical protein expression platforms. Commonly referred to as agroinfiltration, scaled-up versions of this manufacturing process have now become helpful in the fight against global health issues, such as those rapidly evolving virus strains causing influenza or coronavirus disease 2019. In the past decades, considerable efforts have been deployed to improve the efficacy of Agrobacterium-mediated expression, including through the development of new binary vectors, the design of strong promoters, and the deployment of approaches to increase levels and stability of transgene mRNAs. By comparison, much less attention has been given to understanding the effects that agroinfiltration unavoidably has on host plants, including the infiltration process itself, the perception of Agrobacterium and the subsequent accumulation of recombinant products throughout the expression phase. Using the upregulation profiles of plant receptor genes during the heterologous expression of virus-like particles in N. benthamiana leaves, I here describe how some of these host responses interact with each other to form an intricate signalling interplay at the molecular level. I also review host plant's responses to agroinfiltration and highlight strategies that have emerged to improve the efficacy of plant cell biofactories based on the better understanding of this transient expression system.},
}

@article {pmid41385537,
year = {2025},
author = {Takkar, A and Mahesh, KV and Shree, R and Tigari, B and Chatterjee, D and Ahuja, CK and Lal, V},
title = {Neuro-ophthalmology of Infectious Diseases.},
journal = {Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society},
volume = {45},
number = {3},
pages = {362-377},
pmid = {41385537},
issn = {1536-5166},
mesh = {Humans ; *Ophthalmology/methods ; *Eye Infections/diagnosis ; *Neurology ; },
abstract = {BACKGROUND: According to the World Health Organization, infections, particularly sepsis, are linked to over 20% mortality worldwide and are leading cause of morbidity. A variety of infections have neuro-ophthalmic manifestations. The profile of infectious agents, clinical manifestations, severity, and prognosis of these diseases are highly heterogeneous, and it is therefore difficult to make generalized statements about management.

EVIDENCE ACQUISITION: Available literature with regard to individual infectious agents and their neuroophthalmic manifestations or complications was searched using electronic databases such as PubMed, MEDLINE, Scopus, ProQuest, and Embase. The current study is a review of the literature along with the authors' personal experience in this field.

RESULTS: In this review, we describe the key neuro-ophthalmic manifestations of common bacterial, fungal, viral (except HIV, opportunistic infections, and COVID-19 virus), parasitic, and protozoal infections using illustrative examples.

CONCLUSIONS: Infections may involve the afferent and efferent visual pathways, as well as higher order visual processing functions. They can directly invade the eye and the brain or may cause damage due to inflammation, necrosis, vascular compromise, and postinfective demyelination. With the shifting geographic boundaries and widespread international migration, the spectrum of infectious neuro-ophthalmic diseases is expanding. Clinical details, dedicated imaging, biochemical, serological, and at times histopathological confirmation aids in making prompt diagnosis.},
}

Humans
*Ophthalmology/methods
*Eye Infections/diagnosis
*Neurology

@article {pmid41385334,
year = {2025},
author = {Yang, Y and Sun, Y and Kang, X and Wang, Y},
title = {mRNA vaccine platforms and novel delivery systems: From mechanistic principles to clinical translation.},
journal = {Human vaccines & immunotherapeutics},
volume = {21},
number = {1},
pages = {2597629},
doi = {10.1080/21645515.2025.2597629},
pmid = {41385334},
issn = {2164-554X},
mesh = {Humans ; *COVID-19 Vaccines/immunology/administration & dosage ; *Drug Delivery Systems/methods ; *Vaccines, Synthetic/immunology/administration & dosage ; *COVID-19/prevention & control/immunology ; Nanoparticles ; Vaccine Development ; *RNA, Messenger/immunology/administration & dosage/genetics ; *mRNA Vaccines/immunology/administration & dosage ; SARS-CoV-2/immunology ; Vaccines, Virus-Like Particle/administration & dosage/immunology ; },
abstract = {Messenger RNA (mRNA) vaccines have revolutionized the field of vaccinology, offering rapid design flexibility, scalable manufacturing, and strong immunogenicity. The unprecedented success of COVID-19 mRNA vaccines has accelerated research into novel delivery platforms and expanded therapeutic applications beyond infectious diseases to cancer immunotherapy and immune-mediated disorders. This review provides a comprehensive overview of the mechanistic principles underlying mRNA vaccine design, including mRNA engineering strategies, delivery innovations such as lipid nanoparticles (LNPs), polymeric nanoparticles (PNPs), and virus-like particles (VLPs), as well as emerging needle-free administration technologies. We further highlight recent advances in therapeutic areas spanning infectious diseases (e.g. HIV, tuberculosis, respiratory syncytial virus), oncology, and non-traditional indications such as autoimmune disorders. Despite remarkable progress, critical challenges persist in vaccine stability, delivery efficiency, large-scale manufacturing, and global accessibility. Finally, we discuss future research directions integrating artificial intelligence, nanotechnology, and systems immunology to accelerate next-generation mRNA vaccine development and clinical translation.},
}

Humans
*COVID-19 Vaccines/immunology/administration & dosage
*Drug Delivery Systems/methods
*Vaccines, Synthetic/immunology/administration & dosage
*COVID-19/prevention & control/immunology
Nanoparticles
Vaccine Development
*RNA, Messenger/immunology/administration & dosage/genetics
*mRNA Vaccines/immunology/administration & dosage
SARS-CoV-2/immunology
Vaccines, Virus-Like Particle/administration & dosage/immunology

@article {pmid41384659,
year = {2025},
author = {Bessalah, S and Sinha, D and Yuan, X and Paul, S and Longet, S},
title = {[Long COVID: therapeutic challenges and opportunities in the face of persistent sequelae].},
journal = {Medecine sciences : M/S},
volume = {41},
number = {11},
pages = {869-876},
doi = {10.1051/medsci/2025185},
pmid = {41384659},
issn = {1958-5381},
mesh = {Humans ; *COVID-19/complications/therapy/epidemiology ; *SARS-CoV-2/physiology ; Post-Acute COVID-19 Syndrome ; Pandemics ; COVID-19 Drug Treatment ; Antiviral Agents/therapeutic use ; Chronic Disease ; },
abstract = {The COVID-19 pandemic, caused by SARS-CoV-2, has not only led to a global health and economic crisis but also renewed attention to a clinical phenomenon of persistent symptoms after viral infection. This phenomenon is defined as long COVID or post-COVID-19 syndrome. Approximately one in eight patients experience persistent symptoms of varying intensity after the acute phase of the infection. This phenomenon, combined with the virus's high transmissibility and rapid mutation rate, poses a major public health challenge. This review examines various therapeutic approaches currently under consideration for treating long COVID, and explores future prospects in this field.},
}

Humans
*COVID-19/complications/therapy/epidemiology
*SARS-CoV-2/physiology
Post-Acute COVID-19 Syndrome
Pandemics
COVID-19 Drug Treatment
Antiviral Agents/therapeutic use
Chronic Disease

@article {pmid41384439,
year = {2025},
author = {Van Houtte, P and Lamarche, F and Every-Palmer, S},
title = {Effects of face coverings on people and interactions in mental health settings: scoping review.},
journal = {BJPsych open},
volume = {12},
number = {1},
pages = {e11},
doi = {10.1192/bjo.2025.10917},
pmid = {41384439},
issn = {2056-4724},
abstract = {BACKGROUND: Early in the SARS-CoV-2 pandemic, most jurisdictions implemented mandatory face covering policies across healthcare settings. This intervention, which lasted multiple years, was unprecedented in psychiatry. Masks may affect the delivery of mental healthcare, given its reliance on nuanced communication and establishing a therapeutic alliance.

AIMS: This scoping review aimed to provide an overview of the current literature concerning the impact of face masks in mental health settings beyond infection control and identify research gaps to guide future research and policy.

METHOD: Systematic searches were completed in the MEDLINE, Embase, PsycINFO, Scopus and CINAHL databases on 14 August 2024. Articles were eligible if they described peer-reviewed empirical studies involving people with mental disorders or mental health clinicians that reported on impacts of face coverings.

RESULTS: Twenty-eight studies were selected for inclusion, involving 5385 participants. There was considerable heterogeneity among studies. Negative effects of face masks were reported in 26 studies in at least one domain. Themes from the survey-based literature included face masks negatively affecting communication, the therapeutic relationship and overall assessment quality. Experimental studies using emotion recognition tasks showed that people with mental disorders were disadvantaged by masks when interpreting emotions from facial expressions. The most commonly studied population was people with autism spectrum disorder. Children and people with severe or acute mental illness were underrepresented. Only two studies expressly recruited psychiatrists.

CONCLUSIONS: Policy makers should be aware of adverse impacts of mask-wearing in mental health settings and consider these in evolving risk-benefit analyses. Further research is needed to establish the extent of impacts on population subgroups.},
}

@article {pmid41383825,
year = {2025},
author = {Trulik, KG and Kumar, VA and Wu, W and Varma, M and Patel, MM and Manglani, K and Mathew, TA},
title = {Exploring Stress, Fatigue, Burnout, and Resilience Among Healthcare Personnel in Southern and South-Eastern Asia: A Scoping Review.},
journal = {Public health reviews},
volume = {46},
number = {},
pages = {1608603},
pmid = {41383825},
issn = {0301-0422},
abstract = {OBJECTIVES: This study aims to compare methods used to measure burnout, fatigue, stress, and resilience, as well as resilience-building interventions among healthcare personnel (HCP) in Southern and South-eastern Asia. Even before COVID-19, HCP faced high levels of burnout and stress, exacerbated by the pandemic. Identifying effective resilience-building strategies is essential to supporting a healthier workforce.

METHODS: Studies published from January 2016 to December 2021 focusing on burnout, stress, fatigue, and resilience were included. COVIDENCE software was used for screening.

RESULTS: A total of 55 studies were included in the review. Of these 55 studies, 51 measured burnout, stress, fatigue, or resilience, using 77 different instruments. The MBI-HSS, PSS-10, BRS, Brief-COPE, and CD-RISC were the most common tools to assess burnout, stress, and individual resilience. Four studies evaluated resilience interventions, using mindfulness training, meditation, progressive muscle relaxation, and yoga.

CONCLUSION: There are many studies assessing burnout, stress, and resilience among HCP in Southern and South-eastern Asia, yet gaps remain in identifying effective resilience-building interventions. Further research is needed to assess the impact of individual resilience on health systems resilience.},
}

@article {pmid41383811,
year = {2025},
author = {Manivannan, SN and Diaz Arenas, C and Grubaugh, ND and Ogbunugafor, CB},
title = {The importance of epistasis in the evolution of viral pathogens.},
journal = {Virus evolution},
volume = {11},
number = {1},
pages = {veaf091},
pmid = {41383811},
issn = {2057-1577},
abstract = {Understanding the genetic and genomic underpinnings of infectious disease outbreaks has emerged as a frontier of epidemiology. Here, we argue that epistasis-where the phenotypic effects of mutations or gene variants are dictated by the presence of other mutations or genes-should become a focus of genomic epidemiology. To demonstrate this, we present the results of a systematic review of the literature on epistasis in viruses, focusing on three major human viral systems: (i) influenza, (ii) SARS-CoV-2, and (iii) human immunodeficiency virus, as well as two other bodies of the literature mainly focusing on nonhuman viruses: (iv) tobacco etch virus and (v) experimental evolution of viruses. Our systematic review of these five bodies of the literature highlights that epistasis is prevalent in host-virus systems of various kinds, manifesting within and between different loci, with effects of different magnitudes and directions, and shaping various phenotypic traits of epidemiological interest. At the same time, our systematic review demonstrates that our ability to draw general conclusions about the direction and magnitude of epistasis in viral evolution is constrained by several factors: the idiosyncrasies of virus-host systems, biases in the underlying data collection exercises, and the limitations of existing methods. Moving forward, we encourage collaborations between genomic epidemiologists and evolutionary biologists to identify and measure epistasis in studying the evolution of viral pathogens.},
}

@article {pmid41383618,
year = {2025},
author = {Xu, T and Zhang, J and Hou, X and Xie, X and Qi, J and Wang, C and Yan, Y and Kuang, L and Zhu, B},
title = {MIS-C pathogenesis: immune dysregulation & viral triggers.},
journal = {Frontiers in immunology},
volume = {16},
number = {},
pages = {1624963},
pmid = {41383618},
issn = {1664-3224},
mesh = {Humans ; *COVID-19/immunology/complications ; *SARS-CoV-2/immunology ; *Systemic Inflammatory Response Syndrome/immunology/therapy/etiology/virology ; Child ; Immunity, Innate ; Adaptive Immunity ; Cytokine Release Syndrome/immunology ; },
abstract = {Multisystem Inflammatory Syndrome in Children (MIS-C) is a serious condition emerging during the COVID-19 pandemic, strongly associated with prior SARS-CoV-2 infection. Characterized by systemic inflammation affecting multiple organs, MIS-C presents a complex clinical picture including fever, gastrointestinal distress, cardiac dysfunction, and neurological manifestations. Although its exact pathogenesis remains incompletely understood, immune dysregulation is recognized as a central mechanism. This review examines current understanding of MIS-C pathogenesis, focusing on immune dysfunction and viral triggers, particularly SARS-CoV-2. We analyze both innate and adaptive immune responses, cytokine storm dynamics, molecular mimicry, and virus-induced inflammatory cascades. Additionally, we discuss potential immunomodulatory therapeutic strategies and identify future research directions to improve MIS-C management and treatment outcomes.},
}

Humans
*COVID-19/immunology/complications
*SARS-CoV-2/immunology
*Systemic Inflammatory Response Syndrome/immunology/therapy/etiology/virology
Child
Immunity, Innate
Adaptive Immunity
Cytokine Release Syndrome/immunology

@article {pmid41383331,
year = {2025},
author = {Okon, MB and Ugwu, OP and Ugwu, CN and Ogenyi, FC and Swase, DT and Anyanwu, CN and Eze, VHU and Ugwu, JN and Akinola, SA and Mujinya, R and Anyanwu, EG},
title = {From pandemics to preparedness: harnessing AI, CRISPR, and synthetic biology to counter biosecurity threats.},
journal = {Frontiers in public health},
volume = {13},
number = {},
pages = {1711344},
pmid = {41383331},
issn = {2296-2565},
mesh = {Humans ; *Artificial Intelligence ; *Pandemics/prevention & control ; *Synthetic Biology ; *Biosecurity ; *Bioterrorism/prevention & control ; COVID-19/prevention & control ; *Civil Defense/methods ; Global Health ; },
abstract = {Biosecurity threats, which include natural outbreaks, laboratory accidents, and intentional bioterrorism, are a major issue for global health security. The impact of poor preparedness on the health, social, and economic effects of the 1918 influenza pandemic, the 2001 anthrax attacks, and the COVID-19 crisis is devastating. Standard methods, such as quarantine and serology, as well as traditional inoculations, offered basic defences but were often reactive, slow, and unfair. The recent scientific and technological progress has altered the concept of biosecurity preparedness by providing new instruments of early detection, quick reaction, and fair health solutions. Artificial intelligence-based epidemic prediction, next-generation sequencing, CRISPR-based diagnostics, and digital epidemiology are emerging technologies that enable near-real-time surveillance. New therapeutic agents and vaccines, such as mRNA and DNA platforms, monoclonal antibodies, and nanobody therapies, have enhanced response capabilities. Containment measures based on robotics, biosensors, nanotechnology-based PPE, and portable biocontainment units have simultaneously improved frontline safety. Sensitive health information and enhanced coordination are today secured with the help of digital and cyber-biosecurity tools. Nonetheless, the innovations have ethical, legal, and equity issues, which point to the need to govern responsibly and make them accessible to all. This review brings forth the incorporation of emerging technologies with international cooperation, fair systems, and responsive policies as the keys to developing resilient and future-orientated systems that could help alleviate natural, accidental, and intentional biosecurity threats.},
}

Humans
*Artificial Intelligence
*Pandemics/prevention & control
*Synthetic Biology
*Biosecurity
*Bioterrorism/prevention & control
COVID-19/prevention & control
*Civil Defense/methods
Global Health

@article {pmid41380396,
year = {2025},
author = {Ballout, S and Darwish, SA and Kelly, PJ and Keller, T and Shegog, R and Aboul-Enein, BH},
title = {The use of storytelling in COVID-19 vaccine promotion: A scoping review of interventions and campaigns.},
journal = {Vaccine},
volume = {72},
number = {},
pages = {128098},
doi = {10.1016/j.vaccine.2025.128098},
pmid = {41380396},
issn = {1873-2518},
abstract = {BACKGROUND: The development of the COVID-19 vaccine, a groundbreaking scientific advancement, also fueled vaccine hesitancy mainly due to vaccine misinformation and the limited public understanding of the new technology and its rapid pace of development and deployment. A variety of public health communication strategies have been used that include engaging the community in identifying and developing messages, using culturally appropriate communication methods, applying behavioral health principles, and storytelling. The purpose of this scoping review was to assess the most relevant evidence from the research literature on storytelling interventions to mitigate COVID vaccine hesitancy during the pandemic.

METHODS: A scoping review was conducted using the PICOS framework and PRISMA-ScR guidelines, examining studies across 16 databases published between 2020 and October 2025.

RESULTS: Twelve studies met inclusion criteria. Studies involved diverse populations and four implementation themes (cultural relevance, emotional engagement, participant involvement and reach) were identified. The experimental and quasi-experimental studies consistently found that narratives elicited greater emotional engagement, heightened perceived credibility, and stronger identification with the messenger.

CONCLUSION: Storytelling is recognized as a critical component of public health campaigns in its ability to leverage the power of community influencers, such as religious leaders, educators, and local advocates who echo community values. Long-term cohort studies, community-based social marketing campaigns, and qualitative studies are needed to assess specific impacts on vaccination behaviors. Storytelling, when tailored to audience, culture, and context, can contribute to promotion of vaccination, particularly in improving trust, empathy, and misinformation.},
}

@article {pmid41380366,
year = {2025},
author = {Sorotos, M and Firmani, G and Mareş, T and Ceccaroni, A and Santanelli di Pompeo, F},
title = {Epidemiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma - A systematic review of literature.},
journal = {Journal of plastic, reconstructive & aesthetic surgery : JPRAS},
volume = {113},
number = {},
pages = {399-410},
doi = {10.1016/j.bjps.2025.11.038},
pmid = {41380366},
issn = {1878-0539},
abstract = {INTRODUCTION: Breast Implant Associated - Anaplastic Large Cell Lymphoma (BIA-ALCL) cases are steadily increasing worldwide. When considering only the patients with textured implant as the active population, prevalence appears higher than previously reported, and uncertainty regarding incidence rate (IR) trends. We aimed to provide comprehensive estimates by identifying epidemiologic studies reporting prevalence, risk, and IR.

METHODS: A systematic review was conducted up to November 2024 across PubMed, Google Scholar, and Web of Science. Epidemiological data were extracted from the "Patient Registry and Outcomes for Breast Implants and Anaplastic Large Cell Lymphoma Etiology and Epidemiology" (PROFILE) registry (US-specific), Food and Drug Administration (FDA)-Medical Device Reporting (MDR) (US/global), and BIA-ALCL Global Network (worldwide), providing granular data for 2019-2024, enabling yearly IR analysis. All findings were normalized using textured implants patients as the denominator. Interrupted time-series analysis was used to determine the impact of the COVID-19 pandemic on BIA-ALCL reporting.

RESULTS: Among the 1949 studies, 23 were analyzed.

PREVALENCE: 1.0-397.9/100,000 persons; risk: 1:250-1:99,992; and IR 0.021-124/100.000 persons/year. Nationally (US), PROFILE and FDA-MDR data showed IR peaking in 2020 (16.4 and 25.7/100,000) and then declining. Globally, FDA-MDR estimates peaked in 2021 (0.95/100,000) and plummeted in 2022 (0.14/100,000). Global Network data peaked in 2018 (0.68/100,000), dropped in 2020 (0.18/100,000), but rose again in 2024 (0.73/100,000). Significant IR declines (p = 0.02), were identified during the COVID-19 pandemic (2020-2022). Global data suggest transient underreporting and diagnostic delays.

CONCLUSION: BIA-ALCL IR decreased in 2022, then rose globally in 2023-2024, but not in the US, where it continued declining. IR trends were increasing but were influenced by COVID-19, with differences in absolute values likely reflecting smooth vs. textured implant market share variations. Contextualizing epidemiology by surface type and geography remains fundamental.},
}

@article {pmid41223433,
year = {2025},
author = {Worthington, D},
title = {Integration of Virtual Care in the Audiology Service and Beyond.},
journal = {American journal of audiology},
volume = {34},
number = {4},
pages = {767-780},
doi = {10.1044/2025_AJA-25-00149},
pmid = {41223433},
issn = {1558-9137},
mesh = {Humans ; *Telemedicine/organization & administration ; COVID-19 ; *Audiology/organization & administration/methods ; United States ; United States Department of Veterans Affairs ; Pandemics ; SARS-CoV-2 ; Health Services Accessibility ; *Coronavirus Infections/epidemiology ; *Pneumonia, Viral/epidemiology ; Betacoronavirus ; },
abstract = {PURPOSE: This clinical focus article examines the history and evolution of telehealth, emphasizing its technological advancements, integration into health care systems, and the transformative impact of the COVID-19 pandemic on telehealth utilization in the United States, within the private sector and the Veterans Health Administration (VHA). Particular attention is given to the integration of audiology within telehealth, highlighting how the growth and use of teleaudiology services within the VHA have expanded access to this specialized care for Veterans. It aims to clarify how telehealth, including teleaudiology, has been established as a critical modality for enhancing health care access and delivery to Veterans.

CONCLUSIONS: The historical context reveals that, while telehealth has roots tracing back to the American Civil War or earlier, the COVID-19 pandemic catalyzed an unprecedented surge in adoption and integration of telehealth services in both the private sector and the VHA. The data indicate a significant increase in telehealth encounters and patient satisfaction before, during, and after the COVID-19 pandemic, reinforcing its role as a complementary modality alongside traditional in-person care. Challenges such as regulatory barriers and digital access disparities continue to exist, yet ongoing efforts to embed telehealth training in health care education and to foster technological innovation signal a promising future for telehealth. As the health care landscape evolves, telehealth is poised to remain an integral component of patient-centered care.},
}

Humans
*Telemedicine/organization & administration
COVID-19
*Audiology/organization & administration/methods
United States
United States Department of Veterans Affairs
Pandemics
SARS-CoV-2
Health Services Accessibility
*Coronavirus Infections/epidemiology
*Pneumonia, Viral/epidemiology
Betacoronavirus

@article {pmid41128286,
year = {2025},
author = {Ajulo, HK and Alele, FO and Emeto, TI and Adegboye, OA},
title = {Spatial and spatiotemporal machine learning models for COVID-19 dynamics: a review of methodology and reporting practices.},
journal = {Epidemiologic reviews},
volume = {47},
number = {1},
pages = {},
doi = {10.1093/epirev/mxaf017},
pmid = {41128286},
issn = {1478-6729},
mesh = {*COVID-19/epidemiology ; Humans ; *Machine Learning ; *Spatio-Temporal Analysis ; SARS-CoV-2 ; Pandemics ; },
abstract = {COVID-19 has transitioned from a pandemic to an endemic state, but the emergence of novel variants continues to pose significant public health challenges. In this study, the application of spatial and spatiotemporal machine learning (ML) models in understanding the dynamics of COVID-19 was systematically reviewed, as were contextual local-level comprehensive socio-environmental drivers. A systematic search was conducted across the Scopus, Web of Science, PubMed, Emcare (via Ovid), and the World Health Organization COVID-19 databases, and gray literature, adhering to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Data extraction was conducted according to the Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies checklist, and study quality was assessed using a validated scoring system. A total of 42 studies met the inclusion criteria. The review Findings indicate that global-scale spatial and spatiotemporal ML models dominate the field. Long-standing standalone factors in the demographic, environmental, and socioeconomic domains are frequently used as local-level drivers. However, the integration of composite indicators, aggregating multiple standalone factors into a single score, is notably lacking. Such composite indicators have the potential to reduce model complexity, improve interpretability, and enhance performance by capturing multidimensional aspects of vulnerability or risk in a more simplified form. This review highlights critical gaps in the current use of spatial and spatiotemporal ML models to understand the spatial epidemiology of COVID-19. Addressing these gaps could significantly enhance the understanding of COVID-19 dynamics and inform the development of effective public health strategies to mitigate future threats.},
}

*COVID-19/epidemiology
Humans
*Machine Learning
*Spatio-Temporal Analysis
SARS-CoV-2
Pandemics

@article {pmid41102611,
year = {2025},
author = {Karakonstantis, S and Lytras, T and Keske, S and Tsiodras, S and Papst, L and Ioannou, P and Velikov, P and Berg, LP and De Angelis, G and Prendki, V and Adlhoch, C and Penttinen, P and Rello, J and Gavazzi, G and Malhotra-Kumar, S and Skevaki, C and Slafkosky, M and Rath, B},
title = {The Care Continuum of Patients With Influenza in the Post-COVID-19 Era: A Position Paper.},
journal = {The Journal of infectious diseases},
volume = {232},
number = {Supplement_3},
pages = {S333-S346},
doi = {10.1093/infdis/jiaf333},
pmid = {41102611},
issn = {1537-6613},
mesh = {Humans ; *Influenza, Human/therapy/diagnosis ; *COVID-19/epidemiology ; *Continuity of Patient Care ; SARS-CoV-2 ; Health Services Accessibility ; },
abstract = {This position paper addresses the evolving care continuum for patients with respiratory viral infections in the context of the post-coronavirus disease 2019 pandemic phase. We emphasize the need to place the patient at the center of attention from the first signs of influenza-like illness to recovery. Current practices have revealed several deficiencies, such as timely access to healthcare, fragmentation of care, and inadequate follow-up instructions. This article proposes means to address these deficiencies and discusses diagnostic and management considerations for patients with suspected influenza infection.},
}

Humans
*Influenza, Human/therapy/diagnosis
*COVID-19/epidemiology
*Continuity of Patient Care
SARS-CoV-2
Health Services Accessibility

@article {pmid40982324,
year = {2025},
author = {Cruise, C},
title = {Overview of Telehealth in the Department of Veterans Affairs.},
journal = {American journal of audiology},
volume = {34},
number = {4},
pages = {781-784},
doi = {10.1044/2025_AJA-24-00274},
pmid = {40982324},
issn = {1558-9137},
mesh = {Humans ; *Telemedicine/organization & administration/trends ; United States ; *United States Department of Veterans Affairs ; COVID-19/epidemiology ; SARS-CoV-2 ; Health Services Accessibility ; Pandemics ; Veterans ; },
abstract = {BACKGROUND: Telehealth facilitates access to care via technology and broadband infrastructure, remotely connecting patients and their clinical care teams. This is particularly important for those in rural and medically underserved areas, where there may be a lack of specialty medical care, and terrain, weather, or transportation options may make travel to a health care facility difficult.

PURPOSE: The purpose of this clinical focus article is to provide an overview of the history, current state, and future direction of telehealth within the Department of Veterans Affairs.

CONCLUSIONS: A variety of tools and technology with which telehealth can be delivered exist. This enables health care organizations to leverage their clinical networks to match supply and demand across their enterprise and offer additional choices for how patients receive their care. The COVID-19 pandemic was an opportune time for expansion of telehealth. Postpandemic, in many health care systems, it has become a core part of clinical operations. To realize the full potential of telehealth and to ensure equity across populations, addressing gaps in broadband access and digital skills will be critical.},
}

Humans
*Telemedicine/organization & administration/trends
United States
*United States Department of Veterans Affairs
COVID-19/epidemiology
SARS-CoV-2
Health Services Accessibility
Pandemics
Veterans

@article {pmid40010790,
year = {2025},
author = {Chen, JG and Chen, CY and Zhu, K and Ren, XY and Li, HB},
title = {[Interpretation of the Position Paper on Olfactory Dysfunction 2023 (PPOD-23)].},
journal = {Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery},
volume = {60},
number = {2},
pages = {212-216},
doi = {10.3760/cma.j.cn115330-20240428-00246},
pmid = {40010790},
issn = {1673-0860},
support = {2024SF-YBXM-345//Key Research and Development Program of Shaanxi Province/ ; xzy012020046//Basic Research Fund for the Central Universities/ ; 2021JQ-418//Natural Science Foundation of Shaanxi Province Youth Project/ ; },
mesh = {Humans ; COVID-19 ; *Olfaction Disorders/diagnosis/therapy ; Pandemics ; SARS-CoV-2 ; *Coronavirus Infections/complications ; *Pneumonia, Viral ; Betacoronavirus ; Practice Guidelines as Topic ; },
}

Humans
COVID-19
*Olfaction Disorders/diagnosis/therapy
Pandemics
SARS-CoV-2
*Coronavirus Infections/complications
*Pneumonia, Viral
Betacoronavirus
Practice Guidelines as Topic

@article {pmid39905337,
year = {2025},
author = {Pennestrì, F and Cabitza, F and Picerno, N and Banfi, G},
title = {Sharing reliable information worldwide: healthcare strategies based on artificial intelligence need external validation. Position paper.},
journal = {BMC medical informatics and decision making},
volume = {25},
number = {1},
pages = {56},
pmid = {39905337},
issn = {1472-6947},
support = {Ricerca Corrente//Ministero della Salute/ ; },
mesh = {Humans ; *Artificial Intelligence ; *COVID-19 ; *Information Dissemination/methods ; *Machine Learning ; Reproducibility of Results ; SARS-CoV-2 ; },
abstract = {Training machine learning models using data from severe COVID-19 patients admitted to a central hospital, where entire wards are specifically dedicated to COVID-19, may yield predictions that differ significantly from those generated using data collected from patients admitted to a high-volume specialized hospital for orthopedic surgery, where COVID-19 is only a secondary diagnosis. This disparity arises despite the two hospitals being geographically close (within20 kilometers). While machine learning can facilitate rapid public health responses, rigorous external validation and continuous monitoring are essential to ensure reliability and safety.},
}

Humans
*Artificial Intelligence
*COVID-19
*Information Dissemination/methods
*Machine Learning
Reproducibility of Results
SARS-CoV-2

@article {pmid39610162,
year = {2024},
author = {Jacobsen, FF and Glasdam, S and Haukelien, H and van den Muijsenbergh, METC and Ågotnes, G},
title = {Healthy ageing in long-term care? Lessons learned from the COVID-19 pandemic: a position paper.},
journal = {Primary health care research & development},
volume = {25},
number = {},
pages = {e66},
pmid = {39610162},
issn = {1477-1128},
mesh = {Aged ; Aged, 80 and over ; Female ; Humans ; Male ; *COVID-19/epidemiology/prevention & control ; *Frail Elderly ; *Healthy Aging ; *Long-Term Care/organization & administration ; Nursing Homes ; Pandemics ; SARS-CoV-2 ; },
abstract = {AIM: This position paper focuses on healthy ageing for the frailest and institutionalized older adults in the context of the recent pandemic. The paper aims to identify and discuss hindering and promoting factors for healthy ageing in this context, taking both health safety and a meaningful social life into account, in a pandemic situation and beyond.

BACKGROUND: The recent COVID-19 pandemic has highlighted the vulnerability of frail older adults residing in long-term care institutions. This is a segment of the older population that does not seem to align well with the recent policy trend of healthy and active ageing. The need for healthy ageing in this population has been voiced by professionals and interest organizations alike, alluding to inadequate support systems during the pandemic, conditioned by both previous and newly emerging contextual factors. Supporting healthy ageing in older adults in nursing homes and other residential care settings calls for attending to meaningful social life as well as to disease control.

METHODS: Findings and early conclusions leading up to the position paper were presented with peer discussions involving healthcare professionals and researchers at two joint EFPC PRIMORE workshops 2021 and 2022, as well as other international research seminars on long-term care. The following aspects of long-term care and COVID-19 were systematically discussed in those events, with reference to relevant research literature: 1. Long-term care policies, 2. pre-COVID state of long-term care facilities and vulnerability to the pandemic, 3. factors influencing the extent of spread of infection in long-term care facilities, and 4. the challenge of balancing between strict measures for infection control and maintaining a meaningful social life for residents and their significant others.

FINDINGS: A policy shift towards ageing at home and supporting the healthiest of older adults seems to have had unwarranted effects both for frail older adults, their significant others, and professional care staff attending to their needs. Resulting insufficient investment in primary health care staff and in the built environment for frail older adults in nursing homes were detrimental both for the older adults living in nursing homes, their significant others, and staff. More investment in staff and in physical surroundings might improve the quality of care and the social life of older adults in nursing homes in a non-pandemic situation and be a resource for primary health care staff ensuring both protection from health hazards and a meaningful social life for frail older adults in a pandemic or epidemic situation. As for investing in the physical surroundings, smaller nursing homes are advantageous, with singular resident rooms and for developing out-and indoor spaces for socializing and for meeting with families and other visitors. Regarding investment in staff, there is a documented need for educated staff in full-time positions. Use of part-time or temporary staff should be limited.},
}

Aged
Aged, 80 and over
Female
Humans
Male
*COVID-19/epidemiology/prevention & control
*Frail Elderly
*Healthy Aging
*Long-Term Care/organization & administration
Nursing Homes
Pandemics
SARS-CoV-2

@article {pmid39441539,
year = {2025},
author = {Vohra, KP and Johnson, KG and Dalal, A and Ibrahim, S and Krishnan, V and Abbasi-Feinberg, F and Abreu, AR and Bandyopadhyay, A and Gurubhagavatula, I and Kuhlmann, D and Martin, JL and Olson, EJ and Patil, SP and Shelgikar, AV and Trotti, LM and Wickwire, EM and Rowley, JA and Kapur, VK},
title = {Recommendations for permanent sleep telehealth: an American Academy of Sleep Medicine position statement.},
journal = {Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine},
volume = {21},
number = {2},
pages = {401-404},
pmid = {39441539},
issn = {1550-9397},
mesh = {Humans ; *Telemedicine/standards ; United States ; *Sleep Medicine Specialty ; *COVID-19/epidemiology ; *Sleep Wake Disorders/therapy ; Societies, Medical ; Academies and Institutes ; },
abstract = {UNLABELLED: Telehealth use greatly expanded under the Centers for Medicare and Medicaid Services waivers at the start of the COVID-19 pandemic; however, the uncertainty and limitations of continued coverage risks loss of this momentum. Permanent coverage with adequate reimbursement is essential for the long-term acceptance and expansion of telehealth services. Telehealth supports both the current and future need for sleep health management by expanding patient access, increasing clinician efficiency, improving patient safety, and addressing health care equity. Sleep medicine is an ideal field for telehealth due to limited provider access, safety concerns with sleepy patients, availability of remote patient monitoring for treatment management, and the minimal need for repeated physical examinations. Telehealth is noninferior for delivery of cognitive behavioral therapy for insomnia and can enhance obstructive sleep apnea treatment adherence. It is the position of the American Academy of Sleep Medicine that telehealth is an essential tool for the provision of high-quality, patient-centered care for patients with sleep disorders. We encourage all stakeholders including legislators, policymakers, clinicians, and patients to work together to address payment models, interstate care, technology access, prescribing practices, and ongoing research to ensure that sleep telehealth services are permanently available and accessible for all patients seeking sleep medicine care.

CITATION: Vohra KP, Johnson KG, Dalal A, et al. Recommendations for permanent sleep telehealth: an American Academy of Sleep Medicine position statement. J Clin Sleep Med. 2025;21(2):401-404.},
}

Humans
*Telemedicine/standards
United States
*Sleep Medicine Specialty
*COVID-19/epidemiology
*Sleep Wake Disorders/therapy
Societies, Medical
Academies and Institutes

@article {pmid39321629,
year = {2024},
author = {Assiri, AM and Alshahrani, AM and Sakkijha, H and AlGeer, A and Zeitouni, M and AlGohary, M and Dhaini, L and Verma, R and Singh, H},
title = {Transforming respiratory tract infection diagnosis in the kingdom of saudi arabia through point-of-care testing: A white paper for policy makers.},
journal = {Diagnostic microbiology and infectious disease},
volume = {110},
number = {4},
pages = {116530},
doi = {10.1016/j.diagmicrobio.2024.116530},
pmid = {39321629},
issn = {1879-0070},
mesh = {Humans ; COVID-19/diagnosis/epidemiology ; Health Policy ; *Point-of-Care Testing/organization & administration ; *Respiratory Tract Infections/diagnosis/drug therapy/epidemiology ; Saudi Arabia/epidemiology ; },
abstract = {With the evident increased prevalence of respiratory tract infections (RTIs) such as Respiratory Syncytial Virus (RSV), influenza, Group A Streptococcus (GAS), and COVID-19, the conventional diagnostic methods are considered sub-optimal in providing timely management to patients in the Kingdom of Saudi Arabia (KSA). Gaps in current diagnostics are magnified by the Kingdom's unique demographic composition, comprising 11.9 million foreign workers, and the annual influx of over 10 million pilgrims. Current gaps in timely diagnosis leads to delays in treatment, misuse of antibiotics, and protracted hospital stays, subsequently compromising patient care, and escalating healthcare costs. KSA healthcare stakeholders suggest that the integration of rapid molecular Point-of-Care Testing (POCT) into the Kingdom's healthcare infrastructure is an absolute necessity. This publication serves as an urgent call for action aimed at healthcare policymakers in Saudi Arabia, to review the existing diagnostic challenges and include rapid POCTs in the Saudi healthcare strategy for respiratory infections.},
}

Humans
COVID-19/diagnosis/epidemiology
Health Policy
*Point-of-Care Testing/organization & administration
*Respiratory Tract Infections/diagnosis/drug therapy/epidemiology
Saudi Arabia/epidemiology

@article {pmid39074368,
year = {2024},
author = {Snyder Sulmasy, L and Burnett, JR and Carney, JK and DeCamp, M and , },
title = {Ethics and Academic Discourse, Scientific Integrity, Uncertainty, and Disinformation in Medicine: An American College of Physicians Position Paper.},
journal = {Annals of internal medicine},
volume = {177},
number = {9},
pages = {1244-1250},
doi = {10.7326/M24-0648},
pmid = {39074368},
issn = {1539-3704},
mesh = {Humans ; *COVID-19 ; Uncertainty ; *SARS-CoV-2 ; *Ethics, Medical ; *Pandemics ; United States ; Communication ; Pneumonia, Viral ; Betacoronavirus ; },
abstract = {Respect for the scientific process and a diversity of views; open discourse and debate based on principles of ethics, best available evidence, and scientific inquiry and integrity; and an understanding of evidence gaps and uncertainty and how to communicate about them are important values in the advancement of science and the practice of medicine. Physicians often must make decisions about their recommendations to patients in the face of scarce or conflicting data. Are these characteristics of medicine and science widely understood and effectively communicated among members of the profession and to patients and the public? Issues of scientific integrity are longstanding, but COVID-19 brought them to the forefront, in an environment that was sometimes characterized by communication missteps as guidance came and went-or changed-quickly. Today, is open debate flourishing? Have some debates shed more heat than light? Are people losing confidence in science and medicine? In health care institutions? The American College of Physicians explores these issues and offers guidance in this position paper.},
}

Humans
*COVID-19
Uncertainty
*SARS-CoV-2
*Ethics, Medical
*Pandemics
United States
Communication
Pneumonia, Viral
Betacoronavirus

@article {pmid39028203,
year = {2024},
author = {Hsu, VP and Pergam, SA and Shenoy, ES and Banach, DB and Jones Batshon, L and Branch-Elliman, W and Dumyati, G and Haessler, S and Jump, RLP and Malani, AN and Mathew, TA and Murthy, RK and Weber, DJ},
title = {SHEA position statement on pandemic preparedness for policymakers: emerging infectious threats.},
journal = {Infection control and hospital epidemiology},
volume = {45},
number = {7},
pages = {818-820},
doi = {10.1017/ice.2024.64},
pmid = {39028203},
issn = {1559-6834},
mesh = {Humans ; *Pandemics/prevention & control ; Communicable Diseases, Emerging/prevention & control/epidemiology ; COVID-19/prevention & control/epidemiology ; Disaster Planning/organization & administration ; Health Policy ; Pandemic Preparedness ; },
}

Humans
*Pandemics/prevention & control
Communicable Diseases, Emerging/prevention & control/epidemiology
COVID-19/prevention & control/epidemiology
Disaster Planning/organization & administration
Health Policy
Pandemic Preparedness

@article {pmid39002887,
year = {2024},
author = {Freeman, RJ and States, LJ and Lewandowski, SA and Singer, DE and Patankar, SN and Niebuhr, DW},
title = {ACPM Position Statement: Air Pollution and Environmental Justice.},
journal = {American journal of preventive medicine},
volume = {67},
number = {5},
pages = {792-800},
doi = {10.1016/j.amepre.2024.07.003},
pmid = {39002887},
issn = {1873-2607},
mesh = {Humans ; *Air Pollution/adverse effects ; United States ; *COVID-19/prevention & control/epidemiology ; *Environmental Justice ; Environmental Exposure/adverse effects/prevention & control ; Preventive Medicine ; SARS-CoV-2 ; },
abstract = {The American Lung Association's "State of the Air" 2023 report reveals almost 36% of Americans live with unhealthy levels of air pollution. Studies link air pollution with acute respiratory symptoms and exacerbation of respiratory and cardiovascular diseases. Differential air pollution exposures between white and nonwhite communities are significant components of environmental injustices. Even during the coronavirus disease 2019 (COVID-19) lockdown, when the United States experienced significant decreases in polluting activities, these differences persisted. The American College of Preventive Medicine's Science and Translation Committee conducted a nonsystematic literature review to explore initiatives addressing air pollution as a key component of environmental justice, the state of the science regarding health impacts, and evidence supporting mitigations to reduce those impacts. We recommend advocacy for cleaner energy sources and increasing green space; and increasing research, surveillance, and education and training on linkages between air pollutants and health. We recommend preventive medicine physicians raise awareness about increased risks of cardiovascular disease, cancer, asthma, and reduced lung function with air pollution exposure. Preventive medicine physicians may also educate patients and other practitioners about exposures, and how "conventional" disease prevention strategies may have unintended consequences; and influence healthcare leaders to improve efficiency and reduce emissions. We also recommend physicians utilize social determinants of health Z-Codes to capture environmental factors. Private payers should incorporate pollution exposure data into social determinants of health risk adjustments for Medicare Advantage programs. Medicaid agencies should develop provider recommendations for pediatric populations, and states should finance in-home interventions for asthma.},
}

Humans
*Air Pollution/adverse effects
United States
*COVID-19/prevention & control/epidemiology
*Environmental Justice
Environmental Exposure/adverse effects/prevention & control
Preventive Medicine
SARS-CoV-2

@article {pmid38835230,
year = {2024},
author = {Branch-Elliman, W and Banach, DB and Batshon, LJ and Dumyati, G and Haessler, S and Hsu, VP and Jump, RLP and Malani, AN and Mathew, TA and Murthy, RK and Pergam, SA and Shenoy, ES and Weber, DJ},
title = {SHEA position statement on pandemic preparedness for policymakers: pandemic data collection, maintenance, and release.},
journal = {Infection control and hospital epidemiology},
volume = {45},
number = {7},
pages = {821-825},
doi = {10.1017/ice.2024.65},
pmid = {38835230},
issn = {1559-6834},
mesh = {Humans ; *Pandemics/prevention & control ; *Data Collection/methods/standards ; United States ; COVID-19/prevention & control/epidemiology ; Societies, Medical ; Information Dissemination/methods ; Pandemic Preparedness ; },
abstract = {The Society for Healthcare Epidemiology in America (SHEA) strongly supports modernization of data collection processes and the creation of publicly available data repositories that include a wide variety of data elements and mechanisms for securely storing both cleaned and uncleaned data sets that can be curated as clinical and research needs arise. These elements can be used for clinical research and quality monitoring and to evaluate the impacts of different policies on different outcomes. Achieving these goals will require dedicated, sustained and long-term funding to support data science teams and the creation of central data repositories that include data sets that can be "linked" via a variety of different mechanisms and also data sets that include institutional and state and local policies and procedures. A team-based approach to data science is strongly encouraged and supported to achieve the goal of a sustainable, adaptable national shared data resource.},
}

Humans
*Pandemics/prevention & control
*Data Collection/methods/standards
United States
COVID-19/prevention & control/epidemiology
Societies, Medical
Information Dissemination/methods
Pandemic Preparedness

@article {pmid38835229,
year = {2024},
author = {Weber, DJ and Malani, AN and Shenoy, ES and Banach, DB and Batshon, LJ and Branch-Elliman, W and Dumyati, G and Haessler, S and Hsu, VP and Jump, RLP and Mathew, TA and Murthy, RK and Pergam, SA},
title = {Society for Healthcare Epidemiology of America position statement on pandemic preparedness for policymakers: mitigating supply shortages.},
journal = {Infection control and hospital epidemiology},
volume = {45},
number = {7},
pages = {813-817},
doi = {10.1017/ice.2024.67},
pmid = {38835229},
issn = {1559-6834},
mesh = {Humans ; *COVID-19/prevention & control/epidemiology ; United States ; *Personal Protective Equipment/supply & distribution ; Pandemics/prevention & control ; Infection Control/methods/organization & administration ; SARS-CoV-2 ; Strategic Stockpile ; Pandemic Preparedness ; },
abstract = {The COVID-19 has had major direct (e.g., deaths) and indirect (e.g., social inequities) effects in the United States. While the public health response to the epidemic featured some important successes (e.g., universal masking ,and rapid development and approval of vaccines and therapeutics), there were systemic failures (e.g., inadequate public health infrastructure) that overshadowed these successes. Key deficiency in the U.S. response were shortages of personal protective equipment (PPE) and supply chain deficiencies. Recommendations are provided for mitigating supply shortages and supply chain failures in healthcare settings in future pandemics. Some key recommendations for preventing shortages of essential components of infection control and prevention include increasing the stockpile of PPE in the U.S. National Strategic Stockpile, increased transparency of the Stockpile, invoking the Defense Production Act at an early stage, and rapid review and authorization by FDA/EPA/OSHA of non-U.S. approved products. Recommendations are also provided for mitigating shortages of diagnostic testing, medications and medical equipment.},
}

Humans
*COVID-19/prevention & control/epidemiology
United States
*Personal Protective Equipment/supply & distribution
Pandemics/prevention & control
Infection Control/methods/organization & administration
SARS-CoV-2
Strategic Stockpile
Pandemic Preparedness

@article {pmid38835227,
year = {2024},
author = {Banach, DB and Mathew, TA and Batshon, LJ and Branch-Elliman, W and Dumyati, G and Haessler, S and Hsu, VP and Jump, RLP and Malani, AN and Murthy, RK and Pergam, SA and Shenoy, ES and Weber, DJ},
title = {SHEA position statement on pandemic preparedness for policymakers: building a strong and resilient healthcare workforce.},
journal = {Infection control and hospital epidemiology},
volume = {45},
number = {7},
pages = {804-807},
pmid = {38835227},
issn = {1559-6834},
mesh = {Humans ; *COVID-19/prevention & control/epidemiology ; United States/epidemiology ; *Health Workforce ; *Health Personnel ; Pandemics/prevention & control ; SARS-CoV-2 ; Infection Control/methods/organization & administration ; Pandemic Preparedness ; },
abstract = {Throughout the COVID-19 pandemic, many areas in the United States experienced healthcare personnel (HCP) shortages tied to a variety of factors. Infection prevention programs, in particular, faced increasing workload demands with little opportunity to delegate tasks to others without specific infectious diseases or infection control expertise. Shortages of clinicians providing inpatient care to critically ill patients during the early phase of the pandemic were multifactorial, largely attributed to increasing demands on hospitals to provide care to patients hospitalized with COVID-19 and furloughs.[1] HCP shortages and challenges during later surges, including the Omicron variant-associated surges, were largely attributed to HCP infections and associated work restrictions during isolation periods and the need to care for family members, particularly children, with COVID-19. Additionally, the detrimental physical and mental health impact of COVID-19 on HCP has led to attrition, which further exacerbates shortages.[2] Demands increased in post-acute and long-term care (PALTC) settings, which already faced critical staffing challenges difficulty with recruitment, and high rates of turnover. Although individual healthcare organizations and state and federal governments have taken actions to mitigate recurring shortages, additional work and innovation are needed to develop longer-term solutions to improve healthcare workforce resiliency. The critical role of those with specialized training in infection prevention, including healthcare epidemiologists, was well-demonstrated in pandemic preparedness and response. The COVID-19 pandemic underscored the need to support growth in these fields.[3] This commentary outlines the need to develop the US healthcare workforce in preparation for future pandemics.},
}

Humans
*COVID-19/prevention & control/epidemiology
United States/epidemiology
*Health Workforce
*Health Personnel
Pandemics/prevention & control
SARS-CoV-2
Infection Control/methods/organization & administration
Pandemic Preparedness

@article {pmid38835222,
year = {2024},
author = {Hsu, VP and Haessler, S and Banach, DB and Batshon, LJ and Branch-Elliman, W and Dumyati, G and Jump, RLP and Malani, AN and Mathew, TA and Murthy, RK and Pergam, SA and Shenoy, ES and Weber, DJ},
title = {SHEA position statement on pandemic preparedness for policymakers: introduction and overview.},
journal = {Infection control and hospital epidemiology},
volume = {45},
number = {7},
pages = {801-803},
pmid = {38835222},
issn = {1559-6834},
mesh = {Humans ; *COVID-19/epidemiology/prevention & control ; *Pandemics/prevention & control ; SARS-CoV-2 ; United States/epidemiology ; Health Policy ; Pandemic Preparedness ; },
abstract = {Throughout history, pandemics and their aftereffects have spurred society to make substantial improvements in healthcare. After the Black Death in 14[th] century Europe, changes were made to elevate standards of care and nutrition that resulted in improved life expectancy.[1] The 1918 influenza pandemic spurred a movement that emphasized public health surveillance and detection of future outbreaks and eventually led to the creation of the World Health Organization Global Influenza Surveillance Network.[2] In the present, the COVID-19 pandemic exposed many of the pre-existing problems within the US healthcare system, which included (1) a lack of capacity to manage a large influx of contagious patients while simultaneously maintaining routine and emergency care to non-COVID patients; (2) a "just in time" supply network that led to shortages and competition among hospitals, nursing homes, and other care sites for essential supplies; and (3) longstanding inequities in the distribution of healthcare and the healthcare workforce. The decades-long shift from domestic manufacturing to a reliance on global supply chains has compounded ongoing gaps in preparedness for supplies such as personal protective equipment and ventilators. Inequities in racial and socioeconomic outcomes highlighted during the pandemic have accelerated the call to focus on diversity, equity, and inclusion (DEI) within our communities. The pandemic accelerated cooperation between government entities and the healthcare system, resulting in swift implementation of mitigation measures, new therapies and vaccinations at unprecedented speeds, despite our fragmented healthcare delivery system and political divisions. Still, widespread misinformation or disinformation and political divisions contributed to eroded trust in the public health system and prevented an even uptake of mitigation measures, vaccines and therapeutics, impeding our ability to contain the spread of the virus in this country.[3] Ultimately, the lessons of COVID-19 illustrate the need to better prepare for the next pandemic. Rising microbial resistance, emerging and re-emerging pathogens, increased globalization, an aging population, and climate change are all factors that increase the likelihood of another pandemic.[4].},
}

Humans
*COVID-19/epidemiology/prevention & control
*Pandemics/prevention & control
SARS-CoV-2
United States/epidemiology
Health Policy
Pandemic Preparedness

@article {pmid38804606,
year = {2024},
author = {Suen, LW and Incze, M and Simon, C and Englander, H and Bratberg, J and Groves Scott, G and Winograd, R},
title = {Methadone's Resurgence in Bridging the Treatment Gap in the Overdose Crisis: Position Statement of AMERSA, Inc (Association for Multidisciplinary Education, Research, Substance Use, and Addiction).},
journal = {Substance use & addiction journal},
volume = {45},
number = {3},
pages = {337-345},
doi = {10.1177/29767342241255480},
pmid = {38804606},
issn = {2976-7350},
mesh = {Humans ; *Methadone/therapeutic use/poisoning ; *Opiate Substitution Treatment/methods ; United States ; *Opioid-Related Disorders/drug therapy ; *COVID-19 ; *Drug Overdose/drug therapy ; Analgesics, Opioid/poisoning/adverse effects ; Health Services Accessibility ; },
abstract = {BACKGROUND: The United States is grappling with an unprecedented overdose crisis, exacerbated by the proliferation of potent synthetic opioids like illicitly manufactured fentanyl. Despite the efficacy of methadone treatment in managing opioid use disorder, regulatory barriers hinder its widespread utilization. This article examines the complex landscape of methadone regulation across federal, state, and local levels, highlighting disparities and opportunities for reform.

ISSUE: The COVID-19 public health emergency prompted temporary flexibility in methadone regulations, including expanded take-home doses and telehealth counseling, leading to improved treatment experiences and retention. Permanent revisions to federal guidelines have since been introduced by the Substance Abuse and Mental Health Services Administration, reflecting a progressive shift toward patient-centered care and streamlined access. State regulations, managed by Single State Agencies and State Opioid Treatment Authorities, vary widely, often imposing additional restrictions that impede access to methadone treatment. Local OTP clinics further exacerbate barriers through stringent policies, despite federal and state guidelines advocating for flexibility.

RECOMMENDATIONS: Coordinated efforts among policymakers, healthcare providers, and communities are needed to promote the development of accountability measures, incentives, and community involvement to ensure equitable access and quality of care. To truly meet the demand needed to end the existing overdose crisis and enhance accessibility and comprehensive healthcare services, methadone treatment expansion beyond traditional OTP settings into primary care offices and community pharmacies should take place.},
}

Humans
*Methadone/therapeutic use/poisoning
*Opiate Substitution Treatment/methods
United States
*Opioid-Related Disorders/drug therapy
*COVID-19
*Drug Overdose/drug therapy
Analgesics, Opioid/poisoning/adverse effects
Health Services Accessibility

@article {pmid38619233,
year = {2024},
author = {Tomasiewicz, K and Woron, J and Kobayashi, A and Krasinski, Z and Rydzewska, G and Szymanski, FM},
title = {Post-COVID-19 syndrome in everyday clinical practice: interdisciplinary expert position statement endorsed by the Polish Society of Civilization Diseases.},
journal = {Polish archives of internal medicine},
volume = {134},
number = {5},
pages = {},
doi = {10.20452/pamw.16728},
pmid = {38619233},
issn = {1897-9483},
mesh = {Humans ; *COVID-19/complications/therapy ; Poland ; *Post-Acute COVID-19 Syndrome ; SARS-CoV-2 ; },
abstract = {Post-COVID-19 syndrome, also known as long COVID-19 syndrome, is a complex set of symptoms that persist for weeks or months after recovery from an acute phase of COVID-19. These symptoms can affect various body systems, including the respiratory, nervous, cardiovascular, and digestive systems. The most common complaints are fatigue, shortness of breath, joint pain, taste and smell disorders, as well as problems with memory and concentration. Pathogenesis of post-COVID-19 syndrome is complicated and not fully understood, but it is likely related to an overactive immune system, disturbances in the intestinal microbiome, and cell and tissue damage caused by the virus. Incorporating a multidisciplinary approach to treating and rehabilitating patients and further research into this syndrome's underlying mechanisms and therapy are crucial for understanding and effectively treating this complex and multifaceted condition.},
}

Humans
*COVID-19/complications/therapy
Poland
*Post-Acute COVID-19 Syndrome
SARS-CoV-2

@article {pmid38270369,
year = {2024},
author = {Zuin, M and Di Fusco, SA and Zilio, F and Bilato, C and Corda, M and De Luca, L and Di Marco, M and Geraci, G and Iacovoni, A and Milli, M and Navazio, A and Pascale, V and Riccio, C and Scicchitano, P and Urbinati, S and Caldarola, P and Tizzani, E and Gabrielli, D and Colivicchi, F and Grimaldi, M and Oliva, F},
title = {[ANMCO Position paper - 2023 ANMCO States General: Towards a modern Cardiological Community Care].},
journal = {Giornale italiano di cardiologia (2006)},
volume = {25},
number = {2},
pages = {121-125},
doi = {10.1714/4187.41762},
pmid = {38270369},
issn = {1972-6481},
mesh = {Humans ; *Cardiovascular Diseases/therapy ; Pandemics ; *Cardiovascular System ; *Cardiology ; *Cardiologists ; },
abstract = {Over the last two decades, cardiovascular diseases have become the leading cause of chronic disease morbidity and mortality in Italy. Therefore, the chronic cardiovascular care landscape has evolved rapidly in an era of unprecedented demand. Furthermore, the COVID-19 pandemic has highlighted significant deficiencies in existing health and social care systems, especially in the management of chronic cardiovascular disease. In this scenario, the National Reform for Recovery and Resilience (PNRR) may represent a unique opportunity for the development of a new integrated care system between hospital and community. The Italian Association of Hospital Cardiologists (ANMCO) recognizes the need for a statement on the integrated cardiological community care to guide health professionals caring for people with chronic cardiovascular conditions. The aim of the present statement is to outline the evidence for a modern integrated cardiological community care identifying challenges and offering advice for a future transdisciplinary and multi-organizational approach to ensure best practice in the management of chronic cardiovascular disease.},
}

Humans
*Cardiovascular Diseases/therapy
Pandemics
*Cardiovascular System
*Cardiology
*Cardiologists

@article {pmid38146232,
year = {2024},
author = {Campbell, A and Teh, B and Mulligan, S and Ross, DM and Weinkove, R and Gilroy, N and Gangatharan, S and Prince, HM and Szer, J and Trotman, J and Lane, S and Dickinson, M and Quach, H and Enjeti, AK and Ku, M and Gregory, G and Hapgood, G and Ho, PJ and Cochrane, T and Cheah, C and Greenwood, M and Latimer, M and Berkahn, L and Wight, J and Armytage, T and Diamond, P and Tam, CS and Hamad, N},
title = {Australia and New Zealand consensus position statement: use of COVID-19 therapeutics in patients with haematological malignancies.},
journal = {Internal medicine journal},
volume = {54},
number = {2},
pages = {328-336},
doi = {10.1111/imj.16303},
pmid = {38146232},
issn = {1445-5994},
mesh = {Humans ; *COVID-19 ; SARS-CoV-2 ; Consensus ; New Zealand/epidemiology ; *Hematologic Neoplasms/complications/therapy ; },
abstract = {Despite widespread vaccination rates, we are living with high transmission rates of SARS-CoV-2. Although overall hospitalisation rates are falling, the risk of serious infection remains high for patients who are immunocompromised because of haematological malignancies. In light of the ongoing pandemic and the development of multiple agents for treatment, representatives from the Haematology Society of Australia and New Zealand and infectious diseases specialists have collaborated on this consensus position statement regarding COVID-19 management in patients with haematological disorders. It is our recommendation that both patients with haematological malignancies and treating specialists be educated regarding the preventive and treatment options available and that patients continue to receive adequate vaccinations, keeping in mind the suboptimal vaccine responses that occur in haematology patients, in particular, those with B-cell malignancies and on B-cell-targeting or depleting therapy. Patients with haematological malignancies should receive treatment for COVID-19 in accordance with the severity of their symptoms, but even mild infections should prompt early treatment with antiviral agents. The issue of de-isolation following COVID-19 infection and optimal time to treatment for haematological malignancies is discussed but remains an area with evolving data. This position statement is to be used in conjunction with advice from infectious disease, respiratory and intensive care specialists, and current guidelines from the National COVID-19 Clinical Evidence Taskforce and the New Zealand Ministry of Health and Cancer Agency Te Aho o Te Kahu COVID-19 Guidelines.},
}

Humans
*COVID-19
SARS-CoV-2
Consensus
New Zealand/epidemiology
*Hematologic Neoplasms/complications/therapy

@article {pmid38084472,
year = {2024},
author = {Mayorga, C and Çelik, GE and Pascal, M and Hoffmann, HJ and Eberlein, B and Torres, MJ and Brockow, K and Garvey, LH and Barbaud, A and Madrigal-Burgaleta, R and Caubet, JC and Ebo, DG},
title = {Flow-based basophil activation test in immediate drug hypersensitivity. An EAACI task force position paper.},
journal = {Allergy},
volume = {79},
number = {3},
pages = {580-600},
doi = {10.1111/all.15957},
pmid = {38084472},
issn = {1398-9995},
support = {//European Academy of Allergy and Clinical Immunology/ ; },
mesh = {Humans ; Child ; Basophil Degranulation Test/methods ; Basophils ; COVID-19 Vaccines ; *Hypersensitivity, Immediate ; *Drug Hypersensitivity/diagnosis ; *Hypersensitivity ; },
abstract = {Diagnosing immediate drug hypersensitivity reactions (IDHRs) can pose a significant challenge and there is an urgent need for safe and reliable tests. Evidence has emerged that the basophil activation test (BAT), an in vitro assay that mirrors the in vivo response, can be a complementary test for many drugs. In this position paper, members of Task Force (TF) "Basophil activation test in the evaluation of Drug Hypersensitivity Reactions" from the European Academy of Allergy and Clinical Immunology (EAACI) present the data from a survey about the use and utility of BAT in IDHRs in Europe. The survey results indicate that there is a great interest for using BAT especially for diagnosing IDHRs. However, there are still main needs, mainly in the standardization of the protocols. Subsequently consensus-based recommendations were formulated for: (i) Technical aspects of BAT in IDHRs including type of sample, management of drugs, flow cytometry protocols, interpretation of the results; and (ii) Drug-specific aspects that should be taken into account when performing BAT in relation to betalactams, neuromuscular blocking agents, fluoroquinolones, chlorhexidine, opioids, radio contrast media, chemotherapeutics, biological agents, nonsteroidal anti-inflammatory drugs, COVID vaccine, and excipients. Moreover, aspects in the evaluation of pediatric population have also been considered. All this indicates that BAT offers the clinician and laboratory a complementary tool for a safe diagnostic for IDHRs, although its place in the diagnostic algorithm depends on the drug class and patient population (phenotype, geography, and age). The standardization of BAT is important for generalizing this method beyond the individual laboratory.},
}

Humans
Child
Basophil Degranulation Test/methods
Basophils
COVID-19 Vaccines
*Hypersensitivity, Immediate
*Drug Hypersensitivity/diagnosis
*Hypersensitivity

@article {pmid38041429,
year = {2024},
author = {Smolinska, S and Popescu, FD and Izquierdo, E and Antolín-Amérigo, D and Price, OJ and Alvarez-Perea, A and Eguíluz Gracia, I and Papadopoulos, NG and Pfaar, O and Fassio, F and Hoffmann-Sommergruber, K and Dramburg, S and Agache, I and Jutel, M and Brough, HA and Fonseca, JA and Angier, E and Boccabella, C and Bonini, M and Dunn Galvin, A and Gibson, PG and Gawlik, R and Hannachi, F and Kalayci, Ö and Klimek, L and Knibb, R and Matricardi, P and Chivato, T},
title = {Telemedicine with special focus on allergic diseases and asthma-Status 2022: An EAACI position paper.},
journal = {Allergy},
volume = {79},
number = {4},
pages = {777-792},
doi = {10.1111/all.15964},
pmid = {38041429},
issn = {1398-9995},
support = {//European Academy of Allergy and Clinical Immunology/ ; },
mesh = {Humans ; Pandemics ; *Telemedicine/methods ; Confidentiality ; *Hypersensitivity/diagnosis/epidemiology/therapy ; *Asthma/diagnosis/epidemiology/therapy ; },
abstract = {Efficacious, effective and efficient communication between healthcare professionals (HCP) and patients is essential to achieve a successful therapeutic alliance. Telemedicine (TM) has been used for decades but during the COVID-19 pandemic its use has become widespread. This position paper aims to describe the terminology and most important forms of TM among HCP and patients and review the existing studies on the uses of TM for asthma and allergy. Besides, the advantages and risks of TM are discussed, concluding that TM application reduces costs and time for both, HCP and patients, but cannot completely replace face-to-face visits for physical examinations and certain tests that are critical in asthma and allergy. From an ethical point of view, it is important to identify those involved in the TM process, ensure confidentiality and use communication channels that fully guarantee the security of the information. Unmet needs and directions for the future regarding implementation, data protection, privacy regulations, methodology and efficacy are described.},
}

Humans
Pandemics
*Telemedicine/methods
Confidentiality
*Hypersensitivity/diagnosis/epidemiology/therapy
*Asthma/diagnosis/epidemiology/therapy

@article {pmid37877648,
year = {2024},
author = {Chernyshov, PV and Finlay, AY and Tomas-Aragones, L and Tognetti, L and Moscarella, E and Pasquali, P and Manolache, L and Pustisek, N and Svensson, A and Marron, SE and Bewley, A and Salavastru, C and Suru, A and Koumaki, D and Linder, D and Abeni, D and Augustin, M and Blome, C and Salek, SS and Evers, AWM and Poot, F and Sampogna, F and Szepietowski, JС},
title = {Quality of life measurement in teledermatology. Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Teledermatology.},
journal = {Journal of the European Academy of Dermatology and Venereology : JEADV},
volume = {38},
number = {2},
pages = {254-264},
doi = {10.1111/jdv.19570},
pmid = {37877648},
issn = {1468-3083},
mesh = {Child ; Humans ; Quality of Life ; *Venereology ; *Dermatology/methods ; Pandemics ; *Skin Diseases/diagnosis/therapy ; },
abstract = {Many events, including the COVID-19 pandemic, have accelerated the implementation of teledermatology pathways within dermatology departments and across healthcare organizations. Quality of Life (QoL) assessment in dermatology is also a rapidly developing field with a gradual shift from theory to practice. The purpose of this paper organized jointly by the European Academy of Dermatology and Venereology (EADV) Task Force (TF) on QoL and patient-oriented outcomes and the EADV TF on teledermatology is to present current knowledge about QoL assessment during the use of teledermatology approaches, including data on health-related (HR) QoL instruments used in teledermatology, comparison of influence of different treatment methods on HRQoL after face-to-face and teledermatology consultations and to make practical recommendations concerning the assessment of QoL in teledermatology. The EADV TFs made the following position statements: HRQoL assessment may be an important part in most of teledermatology activities; HRQoL assessment may be easily and effectively performed during teledermatology consultations. It is especially important to monitor HRQoL of patients with chronic skin diseases during lockdowns or in areas where it is difficult to reach a hospital for face-to-face consultation; regular assessment of HRQoL of patients with skin diseases during teledermatology consultations may help to monitor therapy efficacy and visualize individual patient's needs; we recommend the use of the DLQI in teledermatology, including the use of the DLQI app which is available in seven languages; it is important to develop apps for dermatology-specific HRQoL instruments for use in children (for example the CDLQI and InToDermQoL) and for disease-specific instruments.},
}

Child
Humans
Quality of Life
*Venereology
*Dermatology/methods
Pandemics
*Skin Diseases/diagnosis/therapy

@article {pmid37831591,
year = {2024},
author = {Rhee, C and Strich, JR and Chiotos, K and Classen, DC and Cosgrove, SE and Greeno, R and Heil, EL and Kadri, SS and Kalil, AC and Gilbert, DN and Masur, H and Septimus, EJ and Sweeney, DA and Terry, A and Winslow, DL and Yealy, DM and Klompas, M},
title = {Improving Sepsis Outcomes in the Era of Pay-for-Performance and Electronic Quality Measures: A Joint IDSA/ACEP/PIDS/SHEA/SHM/SIDP Position Paper.},
journal = {Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
volume = {78},
number = {3},
pages = {505-513},
pmid = {37831591},
issn = {1537-6591},
mesh = {Aged ; Adult ; Humans ; United States ; Reimbursement, Incentive ; Medicare ; *Sepsis/diagnosis/drug therapy ; Systemic Inflammatory Response Syndrome ; Anti-Bacterial Agents/therapeutic use ; *Shock, Septic/diagnosis/therapy ; },
abstract = {The Centers for Medicare & Medicaid Services (CMS) introduced the Severe Sepsis/Septic Shock Management Bundle (SEP-1) as a pay-for-reporting measure in 2015 and is now planning to make it a pay-for-performance measure by incorporating it into the Hospital Value-Based Purchasing Program. This joint IDSA/ACEP/PIDS/SHEA/SHM/SIPD position paper highlights concerns with this change. Multiple studies indicate that SEP-1 implementation was associated with increased broad-spectrum antibiotic use, lactate measurements, and aggressive fluid resuscitation for patients with suspected sepsis but not with decreased mortality rates. Increased focus on SEP-1 risks further diverting attention and resources from more effective measures and comprehensive sepsis care. We recommend retiring SEP-1 rather than using it in a payment model and shifting instead to new sepsis metrics that focus on patient outcomes. CMS is developing a community-onset sepsis 30-day mortality electronic clinical quality measure (eCQM) that is an important step in this direction. The eCQM preliminarily identifies sepsis using systemic inflammatory response syndrome (SIRS) criteria, antibiotic administrations or diagnosis codes for infection or sepsis, and clinical indicators of acute organ dysfunction. We support the eCQM but recommend removing SIRS criteria and diagnosis codes to streamline implementation, decrease variability between hospitals, maintain vigilance for patients with sepsis but without SIRS, and avoid promoting antibiotic use in uninfected patients with SIRS. We further advocate for CMS to harmonize the eCQM with the Centers for Disease Control and Prevention's (CDC) Adult Sepsis Event surveillance metric to promote unity in federal measures, decrease reporting burden for hospitals, and facilitate shared prevention initiatives. These steps will result in a more robust measure that will encourage hospitals to pay more attention to the full breadth of sepsis care, stimulate new innovations in diagnosis and treatment, and ultimately bring us closer to our shared goal of improving outcomes for patients.},
}

Aged
Adult
Humans
United States
Reimbursement, Incentive
Medicare
*Sepsis/diagnosis/drug therapy
Systemic Inflammatory Response Syndrome
Anti-Bacterial Agents/therapeutic use
*Shock, Septic/diagnosis/therapy

@article {pmid37487216,
year = {2023},
author = {Serchen, J and Cline, K and Mathew, S and Hilden, D and , },
title = {Preparing for Future Pandemics and Public Health Emergencies: An American College of Physicians Policy Position Paper.},
journal = {Annals of internal medicine},
volume = {176},
number = {9},
pages = {1240-1244},
doi = {10.7326/M23-0768},
pmid = {37487216},
issn = {1539-3704},
mesh = {Humans ; *COVID-19/epidemiology ; Emergencies ; Pandemics ; Public Health ; Policy ; *Physicians ; },
abstract = {The onset of the COVID-19 pandemic revealed significant gaps in the United States' pandemic and public health emergency response system. At the federal level, government responses were undercut by a lack of centralized coordination, inadequately defined responsibilities, and an under-resourced national stockpile. Contradictory and unclear guidance throughout the early months of the pandemic, along with inconsistent funding to public health agencies, also created notable variance in state and local responses. The lack of a coordinated response added pressure to an already overwhelmed health care system, which was forced to resort to rationing care and personal protective equipment, creating moral distress and trauma for health care workers and their patients. Despite these severe shortcomings, the COVID-19 pandemic also highlighted successful policies and approaches, such as Operation Warp Speed, which led to the fastest development and distribution of a vaccine in history. In this position paper, the American College of Physicians (ACP) offers several policy recommendations for enhancing federal, state, and local preparedness for future pandemic and public health emergencies. This policy paper builds on various statements produced by ACP throughout the COVID-19 pandemic, including on the ethical distribution of vaccinations and resources, conditions to resume economic and social activity, and efforts to protect the health and well-being of medical professionals, among others.},
}

Humans
*COVID-19/epidemiology
Emergencies
Pandemics
Public Health
Policy
*Physicians

@article {pmid37454287,
year = {2023},
author = {Whitcroft, KL and Altundag, A and Balungwe, P and Boscolo-Rizzo, P and Douglas, R and Enecilla, MLB and Fjaeldstad, AW and Fornazieri, MA and Frasnelli, J and Gane, S and Gudziol, H and Gupta, N and Haehner, A and Hernandez, AK and Holbrook, EH and Hopkins, C and Hsieh, JW and Huart, C and Husain, S and Kamel, R and Kim, JK and Kobayashi, M and Konstantinidis, I and Landis, BN and Lechner, M and Macchi, A and Mazal, PP and Miri, I and Miwa, T and Mori, E and Mullol, J and Mueller, CA and Ottaviano, G and Patel, ZM and Philpott, C and Pinto, JM and Ramakrishnan, VR and Roth, Y and Schlosser, RJ and Stjärne, P and Van Gerven, L and Vodicka, J and Welge-Luessen, A and Wormald, PJ and Hummel, T},
title = {Position paper on olfactory dysfunction: 2023.},
journal = {Rhinology},
volume = {61},
number = {33},
pages = {1-108},
doi = {10.4193/Rhin22.483},
pmid = {37454287},
issn = {0300-0729},
mesh = {Humans ; Smell ; Quality of Life ; Pandemics ; *Olfaction Disorders/diagnosis/therapy/epidemiology ; *COVID-19 ; },
abstract = {BACKGROUND: Since publication of the original Position Paper on Olfactory Dysfunction in 2017 (PPOD-17), the personal and societal burden of olfactory disorders has come sharply into focus through the lens of the COVID-19 pandemic. Clinicians, scientists and the public are now more aware of the importance of olfaction, and the impact of its dysfunction on quality of life, nutrition, social relationships and mental health. Accordingly, new basic, translational and clinical research has resulted in significant progress since the PPOD-17. In this updated document, we present and discuss currently available evidence for the diagnosis and management of olfactory dysfunction. Major updates to the current version include, amongst others: new recommendations on olfactory related terminology; new imaging recommendations; new sections on qualitative OD and COVID-19 OD; updated management section. Recommendations were agreed by all co-authors using a modified Delphi process.

CONCLUSIONS: We have provided an overview of current evidence and expert-agreed recommendations for the definition, investigation, and management of OD. As for our original Position Paper, we hope that this updated document will encourage clinicians and researchers to adopt a common language, and in so doing, increase the methodological quality, consistency, and generalisability of work in this field.},
}

Humans
Smell
Quality of Life
Pandemics
*Olfaction Disorders/diagnosis/therapy/epidemiology
*COVID-19

@article {pmid37312802,
year = {2023},
author = {Brody, S and Loree, S and Sampson, M and Mensinkai, S and Coffman, J and Mueller, MH and Askin, N and Hamill, C and Wilson, E and McAteer, MB and Staines, H and , },
title = {Searching for evidence in public health emergencies: a white paper of best practices.},
journal = {Journal of the Medical Library Association : JMLA},
volume = {111},
number = {1-2},
pages = {566-578},
pmid = {37312802},
issn = {1558-9439},
mesh = {Humans ; *Public Health ; *COVID-19 ; Emergencies ; Reproducibility of Results ; Disease Outbreaks ; },
abstract = {OBJECTIVES: Information professionals have supported medical providers, administrators and decision-makers, and guideline creators in the COVID-19 response. Searching COVID-19 literature presented new challenges, including the volume and heterogeneity of literature and the proliferation of new information sources, and exposed existing issues in metadata and publishing. An expert panel developed best practices, including recommendations, elaborations, and examples, for searching during public health emergencies.

METHODS: Project directors and advisors developed core elements from experience and literature. Experts, identified by affiliation with evidence synthesis groups, COVID-19 search experience, and nomination, responded to an online survey to reach consensus on core elements. Expert participants provided written responses to guiding questions. A synthesis of responses provided the foundation for focus group discussions. A writing group then drafted the best practices into a statement. Experts reviewed the statement prior to dissemination.

RESULTS: Twelve information professionals contributed to best practice recommendations on six elements: core resources, search strategies, publication types, transparency and reproducibility, collaboration, and conducting research. Underlying principles across recommendations include timeliness, openness, balance, preparedness, and responsiveness.

CONCLUSIONS: The authors and experts anticipate the recommendations for searching for evidence during public health emergencies will help information specialists, librarians, evidence synthesis groups, researchers, and decision-makers respond to future public health emergencies, including but not limited to disease outbreaks. The recommendations complement existing guidance by addressing concerns specific to emergency response. The statement is intended as a living document. Future revisions should solicit input from a broader community and reflect conclusions of meta-research on COVID-19 and health emergencies.},
}

Humans
*Public Health
*COVID-19
Emergencies
Reproducibility of Results
Disease Outbreaks

@article {pmid37186567,
year = {2023},
author = {Brunetti, ND and Curcio, A and Nodari, S and Parati, G and Carugo, S and Molinari, M and Acquistapace, F and Gensini, G and Molinari, G and , },
title = {The Italian Society of Cardiology and Working Group on Telecardiology and Informatics 2023 updated position paper on telemedicine and artificial intelligence in cardiovascular disease.},
journal = {Journal of cardiovascular medicine (Hagerstown, Md.)},
volume = {24},
number = {Suppl 2},
pages = {e168-e177},
doi = {10.2459/JCM.0000000000001447},
pmid = {37186567},
issn = {1558-2035},
mesh = {Humans ; *Cardiovascular Diseases/diagnosis/therapy ; Artificial Intelligence ; *COVID-19 ; SARS-CoV-2 ; *Cardiology ; *Telemedicine ; Informatics ; },
abstract = {In 2015, the Italian Society of Cardiology and its Working Group on Telemedicine and Informatics issued a position paper on Telecardiology, resuming the most eminent evidence supporting the use of information and communication technology in principal areas of cardiovascular care, ranked by level of evidence. More than 5 years later and after the global shock inflicted by the SARS-CoV-2 pandemic, an update on the topic is warranted. Recent evidence and studies on principal areas of cardiovascular disease will be therefore reported and discussed, with particular focus on telemedicine for cardiovascular care in the COVID-19 context. Novel perspectives and opportunities disclosed by artificial intelligence and its applications in cardiovascular disease will also be discussed. Finally, modalities by which machine learning have realized remote patient monitoring and long-term care in recent years, mainly filtering critical clinical data requiring selective hospital admission, will be provided.},
}

Humans
*Cardiovascular Diseases/diagnosis/therapy
Artificial Intelligence
*COVID-19
SARS-CoV-2
*Cardiology
*Telemedicine
Informatics

@article {pmid37095331,
year = {2023},
author = {Chen, A and Ayub, MH and Mishuris, RG and Rodriguez, JA and Gwynn, K and Lo, MC and Noronha, C and Henry, TL and Jones, D and Lee, WW and Varma, M and Cuevas, E and Onumah, C and Gupta, R and Goodson, J and Lu, AD and Syed, Q and Suen, LW and Heiman, E and Salhi, BA and Khoong, EC and Schmidt, S},
title = {Telehealth Policy, Practice, and Education: a Position Statement of the Society of General Internal Medicine.},
journal = {Journal of general internal medicine},
volume = {38},
number = {11},
pages = {2613-2620},
pmid = {37095331},
issn = {1525-1497},
support = {K23 HL157750/HL/NHLBI NIH HHS/United States ; },
mesh = {Humans ; United States ; Pandemics ; *COVID-19 ; *Telemedicine ; Internal Medicine ; Policy ; },
abstract = {Telehealth services, specifically telemedicine audio-video and audio-only patient encounters, expanded dramatically during the COVID-19 pandemic through temporary waivers and flexibilities tied to the public health emergency. Early studies demonstrate significant potential to advance the quintuple aim (patient experience, health outcomes, cost, clinician well-being, and equity). Supported well, telemedicine can particularly improve patient satisfaction, health outcomes, and equity. Implemented poorly, telemedicine can facilitate unsafe care, worsen disparities, and waste resources. Without further action from lawmakers and agencies, payment will end for many telemedicine services currently used by millions of Americans at the end of 2024. Policymakers, health systems, clinicians, and educators must decide how to support, implement, and sustain telemedicine, and long-term studies and clinical practice guidelines are emerging to provide direction. In this position statement, we use clinical vignettes to review relevant literature and highlight where key actions are needed. These include areas where telemedicine must be expanded (e.g., to support chronic disease management) and where guidelines are needed (e.g., to prevent inequitable offering of telemedicine services and prevent unsafe or low-value care). We provide policy, clinical practice, and education recommendations for telemedicine on behalf of the Society of General Internal Medicine. Policy recommendations include ending geographic and site restrictions, expanding the definition of telemedicine to include audio-only services, establishing appropriate telemedicine service codes, and expanding broadband access to all Americans. Clinical practice recommendations include ensuring appropriate telemedicine use (for limited acute care situations or in conjunction with in-person services to extend longitudinal care relationships), that the choice of modality be done through patient-clinician shared decision-making, and that health systems design telemedicine services through community partnerships to ensure equitable implementation. Education recommendations include developing telemedicine-specific educational strategies for trainees that align with accreditation body competencies and providing educators with protected time and faculty development resources.},
}

Humans
United States
Pandemics
*COVID-19
*Telemedicine
Internal Medicine
Policy

@article {pmid37068276,
year = {2023},
author = {Qaseem, A and MacLean, CH and Tierney, S and Cross, JT and MacDonald, ST and Goldzweig, CL and Fitterman, N and , and Andrews, R and Basch, P and Mathew, SM and McLean, RM and Mount, CA and Powell, RE and Saini, SD},
title = {Performance Measures for Physicians Providing Clinical Care Using Telemedicine: A Position Paper From the American College of Physicians.},
journal = {Annals of internal medicine},
volume = {176},
number = {5},
pages = {694-698},
doi = {10.7326/M23-0140},
pmid = {37068276},
issn = {1539-3704},
mesh = {Humans ; *COVID-19 ; Pandemics ; *Telemedicine/methods ; Delivery of Health Care ; *Physicians ; },
abstract = {There has been an exponential growth in the use of telemedicine services to provide clinical care, accelerated by the COVID-19 pandemic. Clinical care delivered via telemedicine has become a major and accepted method of health care delivery for many patients. There is an urgent need to understand quality of care in the telemedicine environment. This American College of Physicians position paper presents 6 recommendations to ensure the appropriate use of performance measures to evaluate quality of clinical care provided in the telemedicine environment.},
}

Humans
*COVID-19
Pandemics
*Telemedicine/methods
Delivery of Health Care
*Physicians

@article {pmid36976575,
year = {2023},
author = {Franciosi, JP and Berg, EA and Rosen, JM and Lee, JA and Sandberg, KC and Srinath, A and Setty, M and Li, BUK},
title = {North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Statement for Telehealth.},
journal = {Journal of pediatric gastroenterology and nutrition},
volume = {76},
number = {5},
pages = {684-694},
doi = {10.1097/MPG.0000000000003754},
pmid = {36976575},
issn = {1536-4801},
mesh = {Child ; Humans ; *Gastroenterology/education ; *COVID-19 ; Societies ; *Telemedicine ; North America ; Societies, Medical ; },
abstract = {Telehealth (TH) broadly encompasses remote activities of clinical care (telemedicine), provider and patient education, and general health services. The use of synchronous video for TH first occurred in 1964 and then catapulted to the forefront in 2020 during the coronavirus disease 2019 public health emergency. Due to the sudden need for increased TH utilization by nearly all health care providers at that time, TH became essential to clinical practice. However, its sustainable future is unclear in part given that best practices for TH in pediatric gastroenterology (GI), hepatology, and nutrition remain undefined and non-standardized. Key areas for review include historical perspective, general and subspeciality usage, health care disparities, quality of care and the provider-patient interaction, logistics and operations, licensure and liability, reimbursement and insurance coverage, research and quality improvement (QI) priorities, and future use of TH in pediatric GI with a call for advocacy. This position paper from the Telehealth Special Interest Group of North American Society of Gastroenterology, Hepatology and Nutrition provides recommendations for pediatric GI-focused TH best practices, reviews areas for research and QI growth, and presents advocacy opportunities.},
}

Child
Humans
*Gastroenterology/education
*COVID-19
Societies
*Telemedicine
North America
Societies, Medical

@article {pmid36967217,
year = {2023},
author = {Ravi, V and Kapil, A and Biswas, S and Saxena, S},
title = {Indian association of medical microbiologists (IAMM) position paper on guidelines for COVID and SARSCoV2 infections.},
journal = {Indian journal of medical microbiology},
volume = {42},
number = {},
pages = {53-54},
pmid = {36967217},
issn = {1998-3646},
mesh = {Humans ; *COVID-19 ; SARS-CoV-2 ; RNA, Viral ; },
}

Humans
*COVID-19
SARS-CoV-2
RNA, Viral

@article {pmid36940066,
year = {2023},
author = {Dugdale, LS and Esbensen, KL and Sulmasy, LS and , },
title = {Ethical Guidance on Family Caregiving, Support, and Visitation in Hospitals and Residential Health Care Facilities, Including During Public Health Emergencies: an American College of Physicians Position Paper.},
journal = {Journal of general internal medicine},
volume = {38},
number = {8},
pages = {1986-1993},
pmid = {36940066},
issn = {1525-1497},
mesh = {Humans ; *COVID-19/epidemiology ; Public Health ; Pandemics/prevention & control ; Emergencies ; Hospitals ; Delivery of Health Care ; Family/psychology ; },
abstract = {Public health emergencies create challenges for the accommodation of visitors to hospitals and other care facilities. To mitigate the spread of COVID-19 early in the pandemic, health care institutions implemented severe visitor restrictions, many remaining in place more than 2 years, producing serious unintended harms. Visitor restrictions have been associated with social isolation and loneliness, worse physical and mental health outcomes, impaired or delayed decision-making, and dying alone. Patients with disabilities, communication challenges, and cognitive or psychiatric impairments are particularly vulnerable without caregiver presence. This paper critically examines the justifications for, and harms imposed by, visitor restrictions during the COVID-19 pandemic and offers ethical guidance on family caregiving, support, and visitation during public health emergencies. Visitation policies must be guided by ethical principles; incorporate the best available scientific evidence; recognize the invaluable roles of caregivers and loved ones; and involve relevant stakeholders, including physicians, who have an ethical duty to advocate for patients and families during public health crises. Visitor policies should be promptly revised as new evidence emerges regarding benefits and risks in order to prevent avoidable harms.},
}

Humans
*COVID-19/epidemiology
Public Health
Pandemics/prevention & control
Emergencies
Hospitals
Delivery of Health Care
Family/psychology

@article {pmid36918016,
year = {2023},
author = {Behr, J and Berger, M and Blum, TG and Bonella, F and Dinkel, J and Gläser, S and Hagmeyer, L and Kneidinger, N and Koschel, D and Prasse, A and Slevogt, H and Stacher-Priehse, E and Woehrle, H and Kreuter, M},
title = {[SARS-CoV-2-Infection and Interstitial Lung Disease: Position paper of the German Respiratory Society].},
journal = {Pneumologie (Stuttgart, Germany)},
volume = {77},
number = {3},
pages = {143-157},
doi = {10.1055/a-2007-9845},
pmid = {36918016},
issn = {1438-8790},
mesh = {Humans ; *COVID-19 ; SARS-CoV-2 ; *Lung Diseases, Interstitial/diagnosis/therapy ; Lung ; *Pneumonia, Viral/diagnosis/epidemiology/therapy ; },
abstract = {The SARS-CoV-2 pandemic had a tremendous impact on diagnosis and treatment of interstitial lung diseases (ILD). Especially in the early phase of the pandemic, when the delta variant was prevailling, a huge number of viral pneumonias were observed, which worsened pre-existing, triggered de novo occurence or discovery of previously subclincal interstitial lung diseases. The effect of SARS-CoV-2 infection - without or with accompanying viral pneumonia - on the further development of pre-existing ILD as well of new pulmonary inflitrates and consolidiations is difficult to predict and poses a daily challenge to interdisciplinary ILD boards. This position paper of the German Respiratory Society (DGP e.V.) provides answers to the most pressing questions based on current knowledge.},
}

Humans
*COVID-19
SARS-CoV-2
*Lung Diseases, Interstitial/diagnosis/therapy
Lung
*Pneumonia, Viral/diagnosis/epidemiology/therapy

@article {pmid36913975,
year = {2023},
author = {Akbulut, AC and Arisz, RA and Baaten, CCFMJ and Baidildinova, G and Barakzie, A and Bauersachs, R and Ten Berg, J and van den Broek, WWA and de Boer, HC and Bonifay, A and Bröker, V and Buka, RJ and Ten Cate, H and Ten Cate-Hoek, AJ and Cointe, S and De Luca, C and De Simone, I and Diaz, RV and Dignat-George, F and Freson, K and Gazzaniga, G and van Gorp, ECM and Habibi, A and Henskens, YMC and Iding, AFJ and Khan, A and Koenderink, GH and Konkoth, A and Lacroix, R and Lahiri, T and Lam, W and Lamerton, RE and Lorusso, R and Luo, Q and Maas, C and McCarty, OJT and van der Meijden, PEJ and Meijers, JCM and Mohapatra, AK and Nevo, N and Robles, AP and Poncelet, P and Reinhardt, C and Ruf, W and Saraswat, R and Schönichen, C and Schutgens, R and Simioni, P and Spada, S and Spronk, HMH and Tazhibayeva, K and Thachil, J and Diaz, RV and Vallier, L and Veninga, A and Verhamme, P and Visser, C and Watson, SP and Wenzel, P and Willems, RAL and Willers, A and Zhang, P and Zifkos, K and van Zonneveld, AJ},
title = {Blood Coagulation and Beyond: Position Paper from the Fourth Maastricht Consensus Conference on Thrombosis.},
journal = {Thrombosis and haemostasis},
volume = {123},
number = {8},
pages = {808-839},
pmid = {36913975},
issn = {2567-689X},
support = {No 813409//European Union's Horizon 2020 research and innovation program under theMarie Skłodowska-Curie grant agreements No 813409 (TICARDIO), No 722609 (INTRICARE) and 766118 (TAPAS)./ ; },
mesh = {Humans ; Anticoagulants/therapeutic use ; *COVID-19 ; Blood Coagulation ; *Thrombosis ; Hemostasis ; *Blood Coagulation Disorders/drug therapy ; Hemorrhage/drug therapy ; },
abstract = {The Fourth Maastricht Consensus Conference on Thrombosis included the following themes. Theme 1: The "coagulome" as a critical driver of cardiovascular disease. Blood coagulation proteins also play divergent roles in biology and pathophysiology, related to specific organs, including brain, heart, bone marrow, and kidney. Four investigators shared their views on these organ-specific topics. Theme 2: Novel mechanisms of thrombosis. Mechanisms linking factor XII to fibrin, including their structural and physical properties, contribute to thrombosis, which is also affected by variation in microbiome status. Virus infection-associated coagulopathies perturb the hemostatic balance resulting in thrombosis and/or bleeding. Theme 3: How to limit bleeding risks: insights from translational studies. This theme included state-of-the-art methodology for exploring the contribution of genetic determinants of a bleeding diathesis; determination of polymorphisms in genes that control the rate of metabolism by the liver of P2Y12 inhibitors, to improve safety of antithrombotic therapy. Novel reversal agents for direct oral anticoagulants are discussed. Theme 4: Hemostasis in extracorporeal systems: the value and limitations of ex vivo models. Perfusion flow chamber and nanotechnology developments are developed for studying bleeding and thrombosis tendencies. Vascularized organoids are utilized for disease modeling and drug development studies. Strategies for tackling extracorporeal membrane oxygenation-associated coagulopathy are discussed. Theme 5: Clinical dilemmas in thrombosis and antithrombotic management. Plenary presentations addressed controversial areas, i.e., thrombophilia testing, thrombosis risk assessment in hemophilia, novel antiplatelet strategies, and clinically tested factor XI(a) inhibitors, both possibly with reduced bleeding risk. Finally, COVID-19-associated coagulopathy is revisited.},
}

Humans
Anticoagulants/therapeutic use
*COVID-19
Blood Coagulation
*Thrombosis
Hemostasis
*Blood Coagulation Disorders/drug therapy
Hemorrhage/drug therapy

@article {pmid36906502,
year = {2022},
author = {de Sequera, P and Quiroga, B and Goicoechea, M and , },
title = {Update of the prevention and isolation measure recommendations against SARS-COV-2 in dialysis units of Spain: A position paper of the Spanish Society of Nephrology Council.},
journal = {Nefrologia},
volume = {42},
number = {6},
pages = {714-721},
pmid = {36906502},
issn = {2013-2514},
mesh = {Humans ; SARS-CoV-2 ; *COVID-19/prevention & control ; *Nephrology ; Spain/epidemiology ; COVID-19 Vaccines ; Renal Dialysis ; },
abstract = {SARS-CoV-2 pandemic has changed across the last two years. The development and approval of SARS-CoV-2 vaccines and the emergence of new variants has opened up a new scenario. On this regard, Spanish Society of Nephrology (S.E.N.) Council considers that an update of the previous recommendations should be performed. In the present statement, and taking into account the current epidemiological situation, are included updated recommendations of protection and isolation for patients on dialysis programs.},
}

Humans
SARS-CoV-2
*COVID-19/prevention & control
*Nephrology
Spain/epidemiology
COVID-19 Vaccines
Renal Dialysis

@article {pmid36705045,
year = {2023},
author = {Feleszko, W and Okarska-Napierała, M and Buddingh, EP and Bloomfield, M and Sediva, A and Bautista-Rodriguez, C and Brough, HA and Eigenmann, PA and Eiwegger, T and Eljaszewicz, A and Eyerich, S and Gomez-Casado, C and Fraisse, A and Janda, J and Jiménez-Saiz, R and Kallinich, T and Krohn, IK and Mortz, CG and Riggioni, C and Sastre, J and Sokolowska, M and Strzelczyk, Z and Untersmayr, E and Tramper-Stranders, G and , },
title = {Pathogenesis, immunology, and immune-targeted management of the multisystem inflammatory syndrome in children (MIS-C) or pediatric inflammatory multisystem syndrome (PIMS): EAACI Position Paper.},
journal = {Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology},
volume = {34},
number = {1},
pages = {e13900},
doi = {10.1111/pai.13900},
pmid = {36705045},
issn = {1399-3038},
mesh = {SARS-CoV-2 ; Child ; Systemic Inflammatory Response Syndrome/diagnosis/therapy ; Humans ; COVID-19 Vaccines ; *COVID-19/complications ; },
abstract = {Multisystem inflammatory syndrome in children (MIS-C) is a rare, but severe complication of coronavirus disease 2019 (COVID-19). It develops approximately 4 weeks after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and involves hyperinflammation with multisystem injury, commonly progressing to shock. The exact pathomechanism of MIS-C is not known, but immunological dysregulation leading to cytokine storm plays a central role. In response to the emergence of MIS-C, the European Academy of Allergy and Clinical Immunology (EAACI) established a task force (TF) within the Immunology Section in May 2021. With the use of an online Delphi process, TF formulated clinical statements regarding immunological background of MIS-C, diagnosis, treatment, follow-up, and the role of COVID-19 vaccinations. MIS-C case definition is broad, and diagnosis is made based on clinical presentation. The immunological mechanism leading to MIS-C is unclear and depends on activating multiple pathways leading to hyperinflammation. Current management of MIS-C relies on supportive care in combination with immunosuppressive and/or immunomodulatory agents. The most frequently used agents are systemic steroids and intravenous immunoglobulin. Despite good overall short-term outcome, MIS-C patients should be followed-up at regular intervals after discharge, focusing on cardiac disease, organ damage, and inflammatory activity. COVID-19 vaccination is a safe and effective measure to prevent MIS-C. In anticipation of further research, we propose a convenient and clinically practical algorithm for managing MIS-C developed by the Immunology Section of the EAACI.},
}

SARS-CoV-2
Child
Systemic Inflammatory Response Syndrome/diagnosis/therapy
Humans
COVID-19 Vaccines
*COVID-19/complications

@article {pmid36519288,
year = {2023},
author = {DiScala, S and Uritsky, TJ and Brown, ME and Abel, SM and Humbert, NT and Naidu, D},
title = {Society of Pain and Palliative Care Pharmacists White Paper on the Role of Opioid Stewardship Pharmacists.},
journal = {Journal of pain & palliative care pharmacotherapy},
volume = {37},
number = {1},
pages = {3-15},
doi = {10.1080/15360288.2022.2149670},
pmid = {36519288},
issn = {1536-0539},
mesh = {Humans ; *Analgesics, Opioid/adverse effects ; *COVID-19 ; Pain/drug therapy ; Pain Management ; Palliative Care ; Pandemics ; Pharmacists ; United States ; },
abstract = {Opioid stewardship is one essential function of pain and palliative care pharmacists and a critical need in the United States. In recent years, this country has been plagued by two public health emergencies: an opioid crisis and the COVID-19 pandemic, which has exacerbated the opioid epidemic through its economic and psychosocial toll. To develop an opioid stewardship program, a systematic approach is needed. This will be detailed in part here by the Opioid Stewardship Taskforce of the Society of Pain and Palliative Care Pharmacists (SPPCP), focusing on the role of the pharmacist. Many pain and palliative care pharmacists have made significant contributions to the development and daily operation of such programs while also completing other competing clinical tasks, including direct patient care. To ensure dedicated time and attention to critical opioid stewardship efforts, SPPCP recommends and endorses opioid stewardship models employing a full time, opioid stewardship pharmacist in both the inpatient and outpatient setting. Early research suggests that opioid stewardship pharmacists are pivotal to improving opioid metrics and pain care outcomes. However, further research and development in this area of practice is needed and encouraged.},
}

Humans
*Analgesics, Opioid/adverse effects
*COVID-19
Pain/drug therapy
Pain Management
Palliative Care
Pandemics
Pharmacists
United States

@article {pmid36448775,
year = {2022},
author = {Vukoja, M and Kopitovic, I and Lazic, Z and Milenkovic, B and Stankovic, I and Tomic-Spiric, V and Zvezdin, B and Hromis, S and Cekerevac, I and Ilic, A and Vukcevic, M and Dimic-Janjic, S and Stjepanovic, M},
title = {Diagnosis and treatment of adult asthma patients in Serbia: a 2022 experts group position statement.},
journal = {Expert review of respiratory medicine},
volume = {16},
number = {11-12},
pages = {1133-1144},
doi = {10.1080/17476348.2022.2153674},
pmid = {36448775},
issn = {1747-6356},
mesh = {Humans ; Adult ; Serbia ; *Asthma/therapy ; },
abstract = {INTRODUCTION: Asthma is the most common non-communicable chronic lung condition across all ages. Epidemiological data indicate that many asthma patients in Serbia remain undiagnosed and untreated. The implementation of recent global advances in asthma management is limited due to the lack of a systematic approach, drug availability and regulatory affairs. In addition, the global coronavirus disease pandemic has posed a significant challenge, particularly in resource-limited settings.

AREAS COVERED: In this paper, we propose an algorithm for treating adult asthma patients in Serbia. We performed PubMed database search on published asthma clinical trials and guidelines from 1 January 2015 to 10 March 2020. The consensus process incorporated a modified Delphi method that included two rounds of e-mail questionnaires and three rounds of national asthma expert meetings. We focus on 1) objective diagnosis of asthma, 2) the implementation of up-to-date therapeutic options, and 3) the identification and referral of severe asthma patients to newly established severe asthma centers.

EXPERT OPINION: Regional specificities and variations in healthcare systems require the adaptation of evidence-based knowledge. Practical, clinically oriented algorithms designed to overcome local barriers in healthcare delivery may facilitate timely and adequate asthma diagnosis and the local implementation of current advances in asthma management.},
}

Humans
Adult
Serbia
*Asthma/therapy

@article {pmid36427057,
year = {2023},
author = {Strengers, P and O'Brien, SF and Politis, C and Mayr, W and Seifried, E and Spencer, BR},
title = {White paper on pandemic preparedness in the blood supply.},
journal = {Vox sanguinis},
volume = {118},
number = {1},
pages = {8-15},
doi = {10.1111/vox.13378},
pmid = {36427057},
issn = {1423-0410},
mesh = {Humans ; United States ; *COVID-19/epidemiology/prevention & control ; SARS-CoV-2 ; Pandemics/prevention & control ; Austria ; Germany ; },
abstract = {BACKGROUND AND OBJECTIVES: In March 2020, the WHO declared the SARS-CoV-2 corona virus a pandemic which caused a great disruption to global society and had a pronounced effect on the worldwide supply of blood.

MATERIALS AND METHODS: In 2022 an on-line meeting was organised with experts from Austria, Canada, Germany, Greece, Netherlands and United States to explore the opportunities for increasing preparedness within blood systems for a potential future pandemic with similar, or more devastating, consequences. The main themes included the value of preparedness, current risks to the blood supply, supply chain vulnerabilities, and the role of innovation in increasing resiliency and safety.

RESULTS: Seven key recommendations were formulated and including required actions at different levels.

CONCLUSION: Although SARS-CoV-2 might be seen as a unique event, global health risks are expected to increase and will affect blood transfusion medicine if no preparedness plans are developed.},
}

Humans
United States
*COVID-19/epidemiology/prevention & control
SARS-CoV-2
Pandemics/prevention & control
Austria
Germany

@article {pmid36371767,
year = {2023},
author = {Perram, J and Purtill, D and Bajel, A and Butler, J and O'Brien, T and Teh, B and Gilroy, N and Ho, PJ and Doocey, R and Hills, T and Perera, T and Douglas, G and Ramachandran, S and Chee, L and Trotman, J and Weinkove, R and Keogh, S and Fraser, C and Cochrane, T and Watson, AM and Diamond, P and Latimer, M and Irving, I and Blyth, E and Cheah, C and Cole, T and Milliken, S and Yang, H and Greenwood, M and Bardy, P and Kennedy, G and Larsen, S and Conyers, R and Hamad, N},
title = {Australia and New Zealand Transplant and Cellular Therapies (ANZTCT) position statement: COVID-19 management in patients with haemopoietic stem cell transplant and chimeric antigen receptor T cell.},
journal = {Internal medicine journal},
volume = {53},
number = {1},
pages = {119-125},
pmid = {36371767},
issn = {1445-5994},
mesh = {Humans ; *Receptors, Chimeric Antigen/therapeutic use ; *COVID-19 ; New Zealand/epidemiology ; T-Lymphocytes ; *Hematopoietic Stem Cell Transplantation ; },
abstract = {Patients with post-haemopoietic stem cell transplant or chimeric antigen receptor T -cell (CAR-T) therapy face a significant risk of morbidity and mortality from coronavirus disease 2019 because of their immunosuppressed state. As case numbers in Australia and New Zealand continue to rise, guidance on management in this high-risk population is needed. Whilst we have learned much from international colleagues who faced high infection rates early in the pandemic, guidance relevant to local health system structures, medication availability and emerging therapies is essential to equip physicians to manage our patients optimally.},
}

Humans
*Receptors, Chimeric Antigen/therapeutic use
*COVID-19
New Zealand/epidemiology
T-Lymphocytes
*Hematopoietic Stem Cell Transplantation

@article {pmid36272444,
year = {2023},
author = {Sacks-Zimmerman, A and Bergquist, TF and Farr, EM and Cornwell, MA and Kanellopoulos, D},
title = {Rehabilitation of Neuropsychiatric Symptoms in Patients With Long COVID: Position Statement.},
journal = {Archives of physical medicine and rehabilitation},
volume = {104},
number = {2},
pages = {350-354},
pmid = {36272444},
issn = {1532-821X},
mesh = {Adult ; Humans ; Post-Acute COVID-19 Syndrome ; *COVID-19 ; Quality of Life ; *Mental Disorders ; Chronic Disease ; },
abstract = {Long COVID, a term used to describe ongoing symptoms after COVID-19 infection, parallels the course of other postviral syndromes. Neuropsychiatric symptoms of long COVID can be persistent and interfere with quality of life and functioning. Within the biopsychosocial framework of chronic illness, rehabilitation professionals can address the neuropsychiatric sequelae of long COVID. However, current practice models are not designed to address concurrent psychiatric and cognitive symptoms in adults living with long COVID. Thus, we present a biopsychosocial framework for long COVID and provide treatment strategies based on evidence from current literature of postviral chronic illness. These recommendations will guide rehabilitation professionals in identifying common neuropsychiatric symptoms in long COVID that can be targeted for intervention and addressing these symptoms via integrative interventions taking into account the biopsychosocial presentation of long COVID symptoms.},
}

Adult
Humans
Post-Acute COVID-19 Syndrome
*COVID-19
Quality of Life
*Mental Disorders
Chronic Disease

@article {pmid36178109,
year = {2024},
author = {Castelletti, S and Gervasi, S and Ballardini, E and Casasco, M and Cavarretta, E and Colivicchi, F and Contursi, M and Cuccaro, F and D'Ascenzi, F and Gazale, G and Mos, L and Nistri, S and Palmieri, V and Patrizi, G and Scorcu, M and Spampinato, A and Tiberi, M and Zito, GB and Zorzi, A and Zeppilli, P and Sciarra, L and , },
title = {The athlete after COVID-19 infection: what the scientific evidence? What to do? A position statement.},
journal = {Panminerva medica},
volume = {66},
number = {1},
pages = {63-74},
doi = {10.23736/S0031-0808.22.04723-1},
pmid = {36178109},
issn = {1827-1898},
mesh = {Humans ; *COVID-19 ; Athletes ; Exercise ; Pandemics ; *Pericarditis ; },
abstract = {The Coronavirus-19 disease (COVID-19) related pandemic have deeply impacted human health, economy, psychology and sociality. Possible serious cardiac involvement in the infection has been described, raising doubts about complete healing after the disease in many clinical settings. Moreover, there is the suspicion that the vaccines, especially those based on mRNA technology, can induce myopericarditis. Myocarditis or pericarditis related scars can represent the substrate for life-threatening arrhythmias, triggered by physical activity. A crucial point is how to evaluate an athlete after a COVID-19 infection ensuring a safe return to play without increasing the number of unnecessary disqualifications from sports competitions. The lack of conclusive scientific data significantly increases the difficulty to propose recommendations and guidelines on this topic. At the same time, the psychological and physical negative consequences of unnecessary sports restriction must be taken into account. The present document aims to provide an updated brief review of the current knowledge about the COVID-19 cardiac involvement and how to recognize it and to offer a roadmap for the management of the athletes after a COVID-19 infections, including subsequent impact on exercise recommendations. Our document exclusively refers to cardiovascular implications of the disease, but pulmonary consequences are also considered.},
}

Humans
*COVID-19
Athletes
Exercise
Pandemics
*Pericarditis

@article {pmid36117294,
year = {2022},
author = {Filipiak, KJ and Babkowski, MC and Cameli, M and Carugo, S and Ferri, C and Irisov, DB and Narkiewicz, K and Nizamov, U and Pérez de Isla, L and Tomaszuk-Kazberuk, A and Ungar, A and Gąsecka, A},
title = {TIMES TO ACT. Italian-Spanish-Polish-Uzbek Expert Forum Position Paper 2022. Dyslipidemia and arterial hypertension: The two most important and modifiable risk factors in clinical practice.},
journal = {Cardiology journal},
volume = {29},
number = {5},
pages = {730-738},
pmid = {36117294},
issn = {1898-018X},
mesh = {Antihypertensive Agents/therapeutic use ; *COVID-19 ; *Cardiovascular Diseases/diagnosis/epidemiology/prevention & control ; *Dyslipidemias/diagnosis/drug therapy/epidemiology ; Humans ; *Hypertension/diagnosis/drug therapy/epidemiology ; Lipids ; Lipoproteins ; Poland ; Proprotein Convertase 9 ; Risk Factors ; },
abstract = {Hypertension and lipid disorders are two of the main cardiovascular risk factors. Both risk factors - if detected early enough - can be controlled and treated with modern, effective drugs, devoid of significant side effects, available in four countries as different as Italy, Spain, Poland, and Uzbekistan. The aim herein, was to develop this TIMES TO ACT consensus to raise the awareness of the available options of the modern and intensified dyslipidemia and arterial hypertension treatments. The subsequent paragraphs involves consensus and discussion of the deleterious effects of COVID-19 in the cardiovascular field, the high prevalence of hypertension and lipid disorders in our countries and the most important reasons for poor control of these two factors. Subsequently proposed, are currently the most efficient and safe therapeutic options in treating dyslipidemia and arterial hypertension, focusing on the benefits of single-pill combination (SPCs) in both conditions. An accelerated algorithm is proposed to start the treatment with a PCSK9 inhibitor, if the target low-density-lipoprotein values have not been reached. As most patients with hypertension and lipid disorders present with multiple comorbidities, discussed are the possibilities of using new SPCs, combining modern drugs from different therapeutic groups, which mode of action does not confirm the "class effect". We believe our consensus strongly advocates the need to search for patients with cardiovascular risk factors and intensify their lipid-lowering and antihypertensive treatment based on SPCs will improve the control of these two basic cardiovascular risk factors in Italy, Spain, Poland and Uzbekistan.},
}

Antihypertensive Agents/therapeutic use
*COVID-19
*Cardiovascular Diseases/diagnosis/epidemiology/prevention & control
*Dyslipidemias/diagnosis/drug therapy/epidemiology
Humans
*Hypertension/diagnosis/drug therapy/epidemiology
Lipids
Lipoproteins
Poland
Proprotein Convertase 9
Risk Factors

@article {pmid36043581,
year = {2022},
author = {Cheah, FC and Thong, MK and Zulkifli, I and Zilfalil, A and Amir Hamzah, AL and Chan, PWK and Khoo, EJ and Noran, NH},
title = {COVID-19 vaccination for children in Malaysia - A position statement by the College of Paediatrics, Academy of Medicine of Malaysia.},
journal = {The Malaysian journal of pathology},
volume = {44},
number = {2},
pages = {177-185},
pmid = {36043581},
issn = {0126-8635},
mesh = {Adolescent ; *COVID-19/prevention & control ; COVID-19 Vaccines ; Child ; Child, Preschool ; Humans ; Malaysia ; *Pediatrics ; SARS-CoV-2 ; Vaccination ; *Vaccines ; },
abstract = {The availability of COVID-19 vaccines and mass vaccination programmes in adults have significantly reduced the case attack rates and disease burden. COVID-19 vaccination successfully decreases the population at risk of infection, allowing for the safer re-opening of economies and reducing the pandemic's crippling impact on healthcare systems. However, the rapidly mutating severe acute respiratory syndrome-coronavirus-2 poses challenges in diminishing vaccine-induced immunity and vaccinating a significant proportion of adults to achieve herd immunity. These challenges necessitated adolescent vaccination. With the recent emergence of the highly transmissible Omicron variant and the increasing COVID-19 hospitalisation rates of children below 12 years old, many countries opted to also vaccinate younger children. Phase II/III clinical trials and real-world experience demonstrate that COVID-19 vaccinations are effective and safe for younger children and adolescents. Before Malaysia introduced its national COVID-19 vaccination programme for children 5-11 years old (which ran between March and June 2022), an expert advisory statement was issued by the College of Paediatrics, Academy of Medicine of Malaysia, to highlight the benefits and importance of vaccinating children. The advisory statement included clarifications about vaccine-related side effects such as post-vaccination myocarditis and allergic reactions to encourage informed decision making by healthcare providers and parents. This paper, which was prepared based on the critical appraisal of the current evidence, evaluation of the international experiences and the positive impact of COVID-19 vaccination in children, collectively sums up the rationale to support and ensure the success of the nationwide vaccination programme for children. Hence, the College recommends COVID-19 vaccination for children in Malaysia.},
}

Adolescent
*COVID-19/prevention & control
COVID-19 Vaccines
Child
Child, Preschool
Humans
Malaysia
*Pediatrics
SARS-CoV-2
Vaccination
*Vaccines

@article {pmid35970790,
year = {2022},
author = {Feng, LZ and Jiang, HY and Yi, J and Qian, LL and Xu, JD and Zheng, LB and Ma, ZB and Peng, SJ and Jiang, ST and Xu, EF and Chen, LH and Wang, LD and Gao, WZ and Yang, W},
title = {[Introduction and implications of WHO position paper: vaccines against influenza, May 2022].},
journal = {Zhonghua yi xue za zhi},
volume = {102},
number = {30},
pages = {2315-2318},
doi = {10.3760/cma.j.cn112137-20220518-01090},
pmid = {35970790},
issn = {0376-2491},
support = {2021-RC330-002//Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences/ ; INV-023808/GATES/Bill & Melinda Gates Foundation/United States ; },
mesh = {*COVID-19 ; Humans ; *Influenza Vaccines ; *Influenza, Human/epidemiology/prevention & control ; SARS-CoV-2 ; World Health Organization ; },
abstract = {On May 13, 2022, World Health Organization(WHO) Position Paper on Influenza Vaccine (2022 edition) was published. This position paper updates information on influenza epidemiology, high risk population, the impact of immunization on disease, influenza vaccines and effectiveness and safety, and propose WHO's position and recommendation that all countries should consider implementing seasonal influenza vaccine immunization programmes to prepare for an influenza pandemic. In addition, it proposes that the influenza surveillance platform can be integrated with the surveillance of other respiratory viruses, such as SARS-CoV-2 and Respiratory Syncytial Virus. This position paper has some implications for the prevention and control of influenza and other respiratory infectious diseases in China: (1) Optimize influenza vaccine policies to facilitate the implementation of immunization services; (2) Influenza prevention and control should from the perspective of Population Medicine focus on the individual and community to integrate with "Promotion, Prevention, Diagnosis, Control, Treatment, Rehabilitation"; (3) Incorporate prevention and control of other respiratory infectious diseases such as influenza, COVID-19, respiratory syncytial virus and adenovirus, and intelligently monitor by integrating multi-channel data to achieve the goal of co-prevention and control of multiple diseases.},
}

*COVID-19
Humans
*Influenza Vaccines
*Influenza, Human/epidemiology/prevention & control
SARS-CoV-2
World Health Organization

@article {pmid35921761,
year = {2022},
author = {Beretta, GD and Casolino, R and Corsi, DC and Perrone, F and Di Maio, M and Cinieri, S and Gobber, G and Bellani, M and Petrini, F and Zocchi, MT and Traclò, F and Zagonel, V and , and , and , and , and , and , },
title = {Position paper of the Italian Association of Medical Oncology on the impact of COVID-19 on Italian oncology and the path forward: the 2021 Matera statement.},
journal = {ESMO open},
volume = {7},
number = {4},
pages = {100538},
pmid = {35921761},
issn = {2059-7029},
mesh = {*COVID-19 ; Ecosystem ; Humans ; *Medical Oncology ; Neoplasms ; Pandemics ; },
abstract = {The coronavirus disease 2019 (COVID-19) pandemic has severely affected cancer care and research by disrupting the prevention and treatment paths as well as the preclinical, clinical, and translational research ecosystem. In Italy, this has been particularly significant given the severity of the pandemic's impact and the intrinsic vulnerabilities of the national health system. However, whilst detrimental, disruption can also be constructive and may stimulate innovation and progress. The Italian Association of Medical Oncology (AIOM) has recognized the impact of COVID-19 on cancer care continuum and research and proposes the '2021 Matera statement' which aims at providing pragmatic guidance for policymakers and health care institutions to mitigate the impact of the global health crisis on Italian oncology and design the recovery plan for the post-pandemic scenario. The interventions are addressed both to the pillars (prevention, diagnosis, treatment, follow-up, health care professionals) and foundations of cancer care (communication and care relationship, system organization, resources, research, networking). The priorities to be implemented can be summarized in the MATERA acronym: Multidisciplinarity; Access to cancer care; Telemedicine and Territoriality; Equity, ethics, education; Research and resources; Alliance between stakeholders and patients.},
}

*COVID-19
Ecosystem
Humans
*Medical Oncology
Neoplasms
Pandemics

@article {pmid35868584,
year = {2022},
author = {Marjot, T and Eberhardt, CS and Boettler, T and Belli, LS and Berenguer, M and Buti, M and Jalan, R and Mondelli, MU and Moreau, R and Shouval, D and Berg, T and Cornberg, M},
title = {Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper.},
journal = {Journal of hepatology},
volume = {77},
number = {4},
pages = {1161-1197},
pmid = {35868584},
issn = {1600-0641},
support = {102176/B/13/Z/WT_/Wellcome Trust/United Kingdom ; },
mesh = {*COVID-19 ; Humans ; *Liver Diseases/epidemiology/surgery ; *Liver Transplantation ; *Neoplasms ; Pandemics ; SARS-CoV-2 ; },
abstract = {The COVID-19 pandemic has presented a serious challenge to the hepatology community, particularly healthcare professionals and patients. While the rapid development of safe and effective vaccines and treatments has improved the clinical landscape, the emergence of the omicron variant has presented new challenges. Thus, it is timely that the European Association for the Study of the Liver provides a summary of the latest data on the impact of COVID-19 on the liver and issues guidance on the care of patients with chronic liver disease, hepatobiliary cancer, and previous liver transplantation, as the world continues to deal with the consequences of the COVID-19 pandemic.},
}

*COVID-19
Humans
*Liver Diseases/epidemiology/surgery
*Liver Transplantation
*Neoplasms
Pandemics
SARS-CoV-2

@article {pmid35816710,
year = {2022},
author = {Crowley, R and Atiq, O and Hilden, D and , },
title = {Long-Term Services and Supports for Older Adults: A Position Paper From the American College of Physicians.},
journal = {Annals of internal medicine},
volume = {175},
number = {8},
pages = {1172-1174},
doi = {10.7326/M22-0864},
pmid = {35816710},
issn = {1539-3704},
mesh = {Aged ; *Assisted Living Facilities ; *COVID-19/epidemiology ; Humans ; Long-Term Care ; Pandemics ; *Physicians ; United States ; },
abstract = {The number of Americans aged 65 years or older is expected to increase in the coming decades. Because the risk for disability increases with age, more persons will need long-term services and supports (LTSS) to help with bathing, eating, dressing, and other everyday tasks. Long-term services and supports are delivered in nursing homes, assisted living facilities, the person's home, and other settings. However, the LTSS sector faces several challenges, including keeping patients and staff safe during the COVID-19 pandemic, workforce shortages, quality problems, and fragmented coverage options. In this position paper, the American College of Physicians offers policy recommendations on LTSS coverage, financing, workforce, safety and quality, and emergency preparedness and calls on policymakers and other stakeholders to reform and improve the LTSS sector so that care is high quality, accessible, equitable, and affordable.},
}

Aged
*Assisted Living Facilities
*COVID-19/epidemiology
Humans
Long-Term Care
Pandemics
*Physicians
United States

@article {pmid35759767,
year = {2022},
author = {Serchen, J and Atiq, O and Hilden, D and , },
title = {Strengthening Food and Nutrition Security to Promote Public Health in the United States: A Position Paper From the American College of Physicians.},
journal = {Annals of internal medicine},
volume = {175},
number = {8},
pages = {1170-1171},
doi = {10.7326/M22-0390},
pmid = {35759767},
issn = {1539-3704},
mesh = {*COVID-19/epidemiology ; Child ; Humans ; Pandemics/prevention & control ; *Physicians ; Poverty ; Public Health ; United States ; },
abstract = {Food insecurity functions as a social driver of health, directly negatively impacting health status and outcomes, which can further negatively impact employment and income and increase medical expenditures-all of which exacerbates food insecurity. Progress in meaningfully reducing the food-insecurity rate has stalled in recent years. Although rates have decreased since their peak during the Great Recession, these gains have been reversed by the economic implications of the COVID-19 pandemic. As the federal government is the largest provider of food assistance, there is much potential in better leveraging nutrition assistance programs like the Supplemental Nutrition Assistance Program (SNAP) and the Child Nutrition Programs to increase access to healthful foods and improve public health. However, these programs face many funding challenges and internal shortcomings that create uncertainties and prevent maximal effect. Physicians and other medical professionals also have a role in improving nutritional health by screening for food insecurity and serving as connectors between patients, community organizations, and government services. Governments and payers must support these efforts by providing sufficient resources to practices to fulfill this role. In this position paper, the American College of Physicians (ACP) offers several policy recommendations to strengthen the federal food-insecurity response and empower physicians and other medical professionals to better address those social drivers of health occurring beyond the office doors.},
}

*COVID-19/epidemiology
Child
Humans
Pandemics/prevention & control
*Physicians
Poverty
Public Health
United States

@article {pmid35715014,
year = {2022},
author = {Kohan, L and Pellis, Z and Provenzano, DA and Pearson, ACS and Narouze, S and Benzon, HT},
title = {American Society of Regional Anesthesia and Pain Medicine contrast shortage position statement.},
journal = {Regional anesthesia and pain medicine},
volume = {47},
number = {9},
pages = {511-518},
doi = {10.1136/rapm-2022-103830},
pmid = {35715014},
issn = {1532-8651},
mesh = {*Anesthesia, Conduction ; Humans ; Pain ; Pain Management ; *Physicians ; Societies, Medical ; United States ; },
abstract = {The medical field has been experiencing numerous drug shortages in recent years. The most recent shortage to impact the field of interventional pain medicine is that of iodinated contrast medium. Pain physicians must adapt to these changes while maintaining quality of care. This position statement offers guidance on adapting to the shortage.},
}

*Anesthesia, Conduction
Humans
Pain
Pain Management
*Physicians
Societies, Medical
United States

@article {pmid35692364,
year = {2022},
author = {Kaap-Fröhlich, S and Ulrich, G and Wershofen, B and Ahles, J and Behrend, R and Handgraaf, M and Herinek, D and Mitzkat, A and Oberhauser, H and Scherer, T and Schlicker, A and Straub, C and Waury Eichler, R and Wesselborg, B and Witti, M and Huber, M and Bode, SFN},
title = {Position paper of the GMA Committee Interprofessional Education in the Health Professions - current status and outlook.},
journal = {GMS journal for medical education},
volume = {39},
number = {2},
pages = {Doc17},
pmid = {35692364},
issn = {2366-5017},
mesh = {*COVID-19/epidemiology ; Curriculum ; Health Occupations ; Humans ; *Interprofessional Education ; Pandemics ; },
abstract = {In the wake of local initiatives and developmental funding programs, interprofessionality is now included in national curricula in the German-speaking countries. Based on the 3P model (presage, process, product), this position paper presents the development of interprofessional education in recent years in Germany, Austria and Switzerland and places it in an international context. Core aspects as legal frameworks, including amendments to occupational regulations as well as the formation of networks and faculty development are basic requirements for interprofessional education. New topics and educational settings take shape in the process of interprofessional education: patient perspectives and teaching formats, such as online courses, become more important or are newly established. The influence of the COVID-19 pandemic on interprofessional education is explored as well. Among many new interprofessional courses, particularly the implementation of interprofessional training wards in Germany and Switzerland are positive examples of successful interprofessional education. The objective of interprofessional education continues to be the acquisition of interprofessional competencies. The main focus is now centered on evaluating this educational format and testing for the corresponding competencies. In the future, more capacities will be required for interprofessional continuing education and post-graduate education. Structured research programs are essential to ascertain the effects of interprofessional education in the German-speaking countries. In this position paper the GMA committee on interprofessional education encourages further advancement of this topic and expresses the aim to continue cooperating with other networks to strengthen and intensify interprofessional education and collaboration in healthcare.},
}

*COVID-19/epidemiology
Curriculum
Health Occupations
Humans
*Interprofessional Education
Pandemics

@article {pmid35579481,
year = {2022},
author = {Khan, NA and Stergiou, GS and Omboni, S and Kario, K and Renna, N and Chapman, N and McManus, RJ and Williams, B and Parati, G and Konradi, A and Islam, SM and Itoh, H and Mooi, CS and Green, BB and Cho, MC and Tomaszewski, M},
title = {Virtual management of hypertension: lessons from the COVID-19 pandemic-International Society of Hypertension position paper endorsed by the World Hypertension League and European Society of Hypertension.},
journal = {Journal of hypertension},
volume = {40},
number = {8},
pages = {1435-1448},
doi = {10.1097/HJH.0000000000003205},
pmid = {35579481},
issn = {1473-5598},
mesh = {Adult ; Blood Pressure ; Blood Pressure Monitoring, Ambulatory ; *COVID-19 ; Humans ; *Hypertension/diagnosis/drug therapy/epidemiology ; Pandemics ; },
abstract = {The coronavirus disease 2019 pandemic caused an unprecedented shift from in person care to delivering healthcare remotely. To limit infectious spread, patients and providers rapidly adopted distant evaluation with online or telephone-based diagnosis and management of hypertension. It is likely that virtual care of chronic diseases including hypertension will continue in some form into the future. The purpose of the International Society of Hypertension's (ISH) position paper is to provide practical guidance on the virtual management of hypertension to improve its diagnosis and blood pressure control based on the currently available evidence and international experts' opinion for nonpregnant adults. Virtual care represents the provision of healthcare services at a distance with communication conducted between healthcare providers, healthcare users and their circle of care. This statement provides consensus guidance on: selecting blood pressure monitoring devices, accurate home blood pressure assessments, delivering patient education virtually, health behavior modification, medication adjustment and long-term virtual monitoring. We further provide recommendations on modalities for the virtual assessment and management of hypertension across the spectrum of resource availability and patient ability.},
}

Adult
Blood Pressure
Blood Pressure Monitoring, Ambulatory
*COVID-19
Humans
*Hypertension/diagnosis/drug therapy/epidemiology
Pandemics

@article {pmid35533736,
year = {2022},
author = {Burns, SP and Fleming, TK and Webb, SS and Kam, ASH and Fielder, JDP and Kim, GJ and Hu, X and Hill, MT and Kringle, EA},
title = {Stroke Recovery During the COVID-19 Pandemic: A Position Paper on Recommendations for Rehabilitation.},
journal = {Archives of physical medicine and rehabilitation},
volume = {103},
number = {9},
pages = {1874-1882},
pmid = {35533736},
issn = {1532-821X},
support = {K23 HL159240/HL/NHLBI NIH HHS/United States ; },
mesh = {*COVID-19/epidemiology ; Communicable Disease Control ; Humans ; Pandemics ; *Stroke/epidemiology ; *Stroke Rehabilitation ; },
abstract = {Health care delivery shifted and adapted with the COVID-19 pandemic caused by the novel severe acute respiratory syndrome coronavirus 2. Stroke care was negatively affected across the care continuum and may lead to poor community living outcomes in those who survived a stroke during the ongoing pandemic. For instance, delays in seeking care, changes in length of stays, and shifts in discharge patterns were observed during the pandemic. Those seeking care were younger and had more severe neurologic effects from stroke. Increased strain was placed on caregivers and public health efforts, and community-wide lockdowns, albeit necessary to reduce the spread of COVID-19, had detrimental effects on treatment and recommendations to support community living outcomes. The American Congress of Rehabilitation Medicine Stroke Interdisciplinary Special Interest Group Health and Wellness Task Force convened to (1) discuss international experiences in stroke care and rehabilitation and (2) review recently published literature on stroke care and outcomes during the pandemic. Based on the findings in the literature, the task force proposes recommendations and interdisciplinary approaches at the (1) institutional and societal level; (2) health care delivery level; and (3) individual and interpersonal level spanning across the care continuum and into the community.},
}

*COVID-19/epidemiology
Communicable Disease Control
Humans
Pandemics
*Stroke/epidemiology
*Stroke Rehabilitation

@article {pmid35508059,
year = {2022},
author = {Moreira, HG and Oliveira Júnior, MT and Valdigem, BP and Martins, CN and Polanczyk, CA},
title = {Position Statement on Cardiovascular Safety of Vaccines Against COVID-19 - 2022.},
journal = {Arquivos brasileiros de cardiologia},
volume = {118},
number = {4},
pages = {789-796},
pmid = {35508059},
issn = {1678-4170},
mesh = {*COVID-19/prevention & control ; COVID-19 Vaccines/adverse effects ; *Cardiovascular System ; Humans ; SARS-CoV-2 ; *Vaccines ; },
}

*COVID-19/prevention & control
COVID-19 Vaccines/adverse effects
*Cardiovascular System
Humans
SARS-CoV-2
*Vaccines

@article {pmid35460319,
year = {2022},
author = {Rakusa, M and Öztürk, S and Moro, E and Helbok, R and Bassetti, CL and Beghi, E and Bereczki, D and Bodini, B and Di Liberto, G and Jenkins, TM and Macerollo, A and Maia, LF and Martinelli-Boneschi, F and Pisani, A and Priori, A and Sauerbier, A and Soffietti, R and Taba, P and von Oertzen, TJ and Zedde, M and Crean, M and Burlica, A and Cavallieri, F and Sellner, J and , },
title = {COVID-19 vaccination hesitancy among people with chronic neurological disorders: A position paper.},
journal = {European journal of neurology},
volume = {29},
number = {8},
pages = {2163-2172},
pmid = {35460319},
issn = {1468-1331},
mesh = {*COVID-19/complications/prevention & control ; *COVID-19 Vaccines/administration & dosage ; Humans ; *Nervous System Diseases ; Pandemics ; SARS-CoV-2 ; Vaccination/psychology ; *Vaccination Hesitancy ; Post-Acute COVID-19 Syndrome ; },
abstract = {BACKGROUND AND PURPOSE: Health risks associated with SARS-CoV-2 infection are undisputed. Moreover, the capability of vaccination to prevent symptomatic, severe, and fatal COVID-19 is recognized. There is also early evidence that vaccination can reduce the chance for long COVID-19. Nonetheless, the willingness to get vaccinated and receive booster shots remains subpar among people with neurologic disorders. Vaccine scepticism not only jeopardizes collective efforts to end the COVID-19 pandemic but puts individual lives at risk, as some chronic neurologic diseases are associated with a higher risk for an unfavorable COVID-19 course.

METHODS: In this position paper, the NeuroCOVID-19 Task Force of the European Academy of Neurology (EAN) summarizes the current knowledge on the prognosis of COVID-19 among patients with neurologic disease, elucidates potential barriers to vaccination coverage, and formulates strategies to overcome vaccination hesitancy. A survey among the Task Force members on the phenomenon of vaccination hesitancy among people with neurologic disease supports the lines of argumentation.

RESULTS: The study revealed that people with multiple sclerosis and other nervous system autoimmune disorders are most skeptical of SARS-CoV-2 vaccination. The prevailing concerns included the chance of worsening the pre-existing neurological condition, vaccination-related adverse events, and drug interaction.

CONCLUSIONS: The EAN NeuroCOVID-19 Task Force reinforces the key role of neurologists as advocates of COVID-19 vaccination. Neurologists need to argue in the interest of their patients about the overwhelming individual and global benefits of COVID-19 vaccination. Moreover, they need to keep on eye on this vulnerable patient group, its concerns, and the emergence of potential safety signals.},
}

*COVID-19/complications/prevention & control
*COVID-19 Vaccines/administration & dosage
Humans
*Nervous System Diseases
Pandemics
SARS-CoV-2
Vaccination/psychology
*Vaccination Hesitancy
Post-Acute COVID-19 Syndrome

@article {pmid35434988,
year = {2022},
author = {Parthasaradhi, A and Ganguly, S and Kar, BR and Thomas, J and Neema, S and Tahiliani, S and Sathishkumar, D and Parasramani, SG and Chalam, KV and Komeravalli, H},
title = {Coronavirus disease 2019 vaccination in patients with psoriasis: A position statement from India by SIG psoriasis (IADVL Academy).},
journal = {Indian journal of dermatology, venereology and leprology},
volume = {88},
number = {3},
pages = {286-290},
doi = {10.25259/IJDVL_773_2021},
pmid = {35434988},
issn = {0973-3922},
mesh = {*COVID-19/epidemiology/prevention & control ; COVID-19 Vaccines ; Humans ; India/epidemiology ; *Psoriasis/diagnosis/drug therapy/epidemiology ; SARS-CoV-2 ; Vaccination ; *Vaccines ; },
abstract = {Coronavirus disease 2019 (COVID-19) pandemic has affected every sphere of life including management of psoriasis. The availability of COVID-19 vaccines has given rise to hope and at the same time some apprehensions as well. With the general population becoming eligible for vaccination, there is some confusion, on the eligibility of patients with different medical conditions and patients on immunosuppressive or immunomodulating medications for COVID-19 vaccination. Dermatologists treating psoriasis patients frequently face questions from them, whether they can undergo coronavirus disease 2019 vaccination. A PUBMED search was performed using the following strategy: 'COVID-19' AND 'Vaccine' AND 'Psoriasis'. We also performed a PUBMED search using the following strategy: 'SARS-CoV-2' AND 'Vaccine' AND 'Psoriasis'. All articles irrespective of language and publication date were included to arrive at this position statement. This position statement deals with the safety, eligibility and modifications of treatment, if needed among psoriasis patients with regards to the coronavirus disease 2019 vaccines currently available in India.},
}

*COVID-19/epidemiology/prevention & control
COVID-19 Vaccines
Humans
India/epidemiology
*Psoriasis/diagnosis/drug therapy/epidemiology
SARS-CoV-2
Vaccination
*Vaccines

@article {pmid35343485,
year = {2021},
author = {Violini, R and De Rosa, S and Leonardi, S and Doronzo, B and Cremonesi, A and Callea, G and Spandonaro, F and Tarantini, G and Esposito, G and Cernetti, C and Indolfi, C and Berti, S and Marchese, A and Saia, F and Monti, F},
title = {[GISE (Italian Society of Interventional Cardiology) Position paper: Short-term hospitalization for percutaneous coronary intervention; a helpful tool to manage post-COVID-19 backlogs].},
journal = {Giornale italiano di cardiologia (2006)},
volume = {22},
number = {12 Suppl 2},
pages = {4-15},
doi = {10.1714/3723.37134},
pmid = {35343485},
issn = {1972-6481},
mesh = {*COVID-19 ; *Cardiology ; Hospitalization ; Humans ; Length of Stay ; Pandemics/prevention & control ; *Percutaneous Coronary Intervention/adverse effects ; },
abstract = {Minimization of hospital lengths of stay has always been a key goal for healthcare systems. More so during the current COVID-19 pandemic. In fact, we have faced a reduction in no-COVID-19 admissions with the generation of huge backlogs. Low-risk patients undergoing elective percutaneous coronary intervention (PCI) can be candidate for short-term hospitalization, with consequent reduction of waiting lists. Several single-center and multicenter observational studies, multiple randomized trials and some meta-analyses have addressed this topic.In this position paper, we present a proposal for short hospitalization for elective PCI procedures in selected patients who present complications only exceptionally and exclusively immediately after the procedure, if the inclusion and exclusion criteria are met. Each Center can choose between admission in day surgery or one day surgery, extending hospital length of stay only for patients who present complications or who are candidate for urgent surgery. Short-term hospitalization considerably reduces costs even if, with the current model, it generally results in a parallel reduction in reimbursement. Hence, we present an actual model, already tested successfully in an Italian hospital, that warrants sustainability. This approach can then be tailored to single Centers.},
}

*COVID-19
*Cardiology
Hospitalization
Humans
Length of Stay
Pandemics/prevention & control
*Percutaneous Coronary Intervention/adverse effects

@article {pmid35240931,
year = {2022},
author = {Kwasnicka, D and Keller, J and Perski, O and Potthoff, S and Ten Hoor, GA and Ainsworth, B and Crutzen, R and Dohle, S and van Dongen, A and Heino, M and Henrich, JF and Knox, L and König, LM and Maltinsky, W and McCallum, C and Nalukwago, J and Neter, E and Nurmi, J and Spitschan, M and Van Beurden, SB and Van der Laan, LN and Wunsch, K and Levink, JJJ and Sanderman, R},
title = {White Paper: Open Digital Health - accelerating transparent and scalable health promotion and treatment.},
journal = {Health psychology review},
volume = {16},
number = {4},
pages = {475-491},
doi = {10.1080/17437199.2022.2046482},
pmid = {35240931},
issn = {1743-7202},
mesh = {Humans ; *Pandemics/prevention & control ; *COVID-19 ; Health Promotion ; Global Health ; },
abstract = {In this White Paper, we outline recommendations from the perspective of health psychology and behavioural science, addressing three research gaps: (1) What methods in the health psychology research toolkit can be best used for developing and evaluating digital health tools? (2) What are the most feasible strategies to reuse digital health tools across populations and settings? (3) What are the main advantages and challenges of sharing (openly publishing) data, code, intervention content and design features of digital health tools? We provide actionable suggestions for researchers joining the continuously growing Open Digital Health movement, poised to revolutionise health psychology research and practice in the coming years. This White Paper is positioned in the current context of the COVID-19 pandemic, exploring how digital health tools have rapidly gained popularity in 2020-2022, when world-wide health promotion and treatment efforts rapidly shifted from face-to-face to remote delivery. This statement is written by the Directors of the not-for-profit Open Digital Health initiative (n = 6), Experts attending the European Health Psychology Society Synergy Expert Meeting (n = 17), and the initiative consultant, following a two-day meeting (19-20th August 2021).},
}

Humans
*Pandemics/prevention & control
*COVID-19
Health Promotion
Global Health

@article {pmid35112371,
year = {2022},
author = {Barbaud, A and Garvey, LH and Arcolaci, A and Brockow, K and Mori, F and Mayorga, C and Bonadonna, P and Atanaskovic-Markovic, M and Moral, L and Zanoni, G and Pagani, M and Soria, A and Jošt, M and Caubet, JC and Carmo, A and Mona, AA and Alvarez-Perea, A and Bavbek, S and Benedetta, B and Bilo, MB and Blanca-López, N and Bogas, HG and Buonomo, A and Calogiuri, G and Carli, G and Cernadas, J and Cortellini, G and Celik, G and Demir, S and Doña, I and Dursun, AB and Eberlein, B and Faria, E and Fernandes, B and Garcez, T and Garcia-Nunez, I and Gawlik, R and Gelincik, A and Gomes, E and Gooi, JHC and Grosber, M and Gülen, T and Hacard, F and Hoarau, C and Janson, C and Johnston, SL and Joerg, L and Kepil Özdemir, S and Klimek, L and Košnik, M and Kowalski, ML and Kuyucu, S and Kvedariene, V and Laguna, JJ and Lombardo, C and Marinho, S and Merk, H and Meucci, E and Morisset, M and Munoz-Cano, R and Murzilli, F and Nakonechna, A and Popescu, FD and Porebski, G and Radice, A and Regateiro, FS and Röckmann, H and Romano, A and Sargur, R and Sastre, J and Scherer Hofmeier, K and Sedláčková, L and Sobotkova, M and Terreehorst, I and Treudler, R and Walusiak-Skorupa, J and Wedi, B and Wöhrl, S and Zidarn, M and Zuberbier, T and Agache, I and Torres, MJ},
title = {Allergies and COVID-19 vaccines: An ENDA/EAACI Position paper.},
journal = {Allergy},
volume = {77},
number = {8},
pages = {2292-2312},
doi = {10.1111/all.15241},
pmid = {35112371},
issn = {1398-9995},
mesh = {*Anaphylaxis/diagnosis ; *COVID-19/prevention & control ; *COVID-19 Vaccines/adverse effects ; *Drug Hypersensitivity/diagnosis/etiology/therapy ; Humans ; *Vaccines ; Vaccines, Synthetic ; mRNA Vaccines ; },
abstract = {BACKGROUND: Anaphylaxis, which is rare, has been reported after COVID-19 vaccination, but its management is not standardized.

METHOD: Members of the European Network for Drug Allergy and the European Academy of Allergy and Clinical Immunology interested in drug allergy participated in an online questionnaire on pre-vaccination screening and management of allergic reactions to COVID-19 vaccines, and literature was analysed.

RESULTS: No death due to anaphylaxis to COVID-19 vaccines has been confirmed in scientific literature. Potential allergens, polyethylene glycol (PEG), polysorbate and tromethamine are excipients. The authors propose allergy evaluation of persons with the following histories: 1-anaphylaxis to injectable drug or vaccine containing PEG or derivatives; 2-anaphylaxis to oral/topical PEG containing products; 3-recurrent anaphylaxis of unknown cause; 4-suspected or confirmed allergy to any mRNA vaccine; and 5-confirmed allergy to PEG or derivatives. We recommend a prick-to-prick skin test with the left-over solution in the suspected vaccine vial to avoid waste. Prick test panel should include PEG 4000 or 3500, PEG 2000 and polysorbate 80. The value of in vitro test is arguable.

CONCLUSIONS: These recommendations will lead to a better knowledge of the management and mechanisms involved in anaphylaxis to COVID-19 vaccines and enable more people with history of allergy to be vaccinated.},
}

*Anaphylaxis/diagnosis
*COVID-19/prevention & control
*COVID-19 Vaccines/adverse effects
*Drug Hypersensitivity/diagnosis/etiology/therapy
Humans
*Vaccines
Vaccines, Synthetic
mRNA Vaccines

@article {pmid35103926,
year = {2022},
author = {Cosentini, R and Groff, P and Brambilla, AM and Camajori Todeschini, R and Gangitano, G and Ingrassia, S and Marino, R and Nori, F and Pagnozzi, F and Panero, F and Ferrari, R and , },
title = {SIMEU position paper on non-invasive respiratory support in COVID-19 pneumonia.},
journal = {Internal and emergency medicine},
volume = {17},
number = {4},
pages = {1175-1189},
pmid = {35103926},
issn = {1970-9366},
mesh = {*COVID-19/complications/therapy ; *Emergency Medicine ; Humans ; *Noninvasive Ventilation/methods ; Respiration, Artificial ; *Respiratory Insufficiency ; SARS-CoV-2 ; },
abstract = {The rapid worldwide spread of the Coronavirus disease (COVID-19) crisis has put health systems under pressure to a level never experienced before, putting intensive care units in a position to fail to meet an exponentially growing demand. The main clinical feature of the disease is a progressive arterial hypoxemia which rapidly leads to ARDS which makes the use of intensive care and mechanical ventilation almost inevitable. The difficulty of health systems to guarantee a corresponding supply of resources in intensive care, together with the uncertain results reported in the literature with respect to patients who undergo early conventional ventilation, make the search for alternative methods of oxygenation and ventilation and potentially preventive of the need for tracheal intubation, such as non-invasive respiratory support techniques particularly valuable. In this context, the Emergency Department, located between the area outside the hospital and hospital ward and ICU, assumes the role of a crucial junction, due to the possibility of applying these techniques at a sufficiently early stage and being able to rapidly evaluate their effectiveness. This position paper describes the indications for the use of non-invasive respiratory support techniques in respiratory failure secondary to COVID-19-related pneumonia, formulated by the Non-invasive Ventilation Faculty of the Italian Society of Emergency Medicine (SIMEU) on the base of what is available in the literature and on the authors' direct experience. Rationale, literature, tips & tricks, resources, risks and expected results, and patient interaction will be discussed for each one of the escalating non-invasive respiratory techniques: standard oxygen, HFNCO, CPAP, NIPPV, and awake self-repositioning. The final chapter describes our suggested approach to the failing patient.},
}

*COVID-19/complications/therapy
*Emergency Medicine
Humans
*Noninvasive Ventilation/methods
Respiration, Artificial
*Respiratory Insufficiency
SARS-CoV-2

@article {pmid34973937,
year = {2022},
author = {Manzano-Aquiahuatl, C and Tobar-Fredes, R and Zavala-Solares, MR and Salle-Levy, D and Imamura, R and Morales-Fernández, R and Ojeda-Peña, L and Parra-Reyes, D and Santoro, P and Ton, V and Trujillo-Benavides, OE and Vargas-García, MA and Furkim, AM},
title = {Position statement of the Latin American Dysphagia Society for the management of oropharyngeal and esophageal dysphagia during the COVID-19 pandemic.},
journal = {Revista de gastroenterologia de Mexico (English)},
volume = {87},
number = {1},
pages = {63-79},
pmid = {34973937},
issn = {2255-534X},
mesh = {*COVID-19 ; *Deglutition Disorders/epidemiology/therapy ; Humans ; Latin America/epidemiology ; Pandemics ; SARS-CoV-2 ; },
abstract = {INTRODUCTION: The SARS-CoV-2 virus that causes the COVID-19 disease is transmitted through the inhalation of droplets or aerosols and inoculation via the oronasal or ocular routes, transforming the management of swallowing disorders into a challenge for healthcare teams, given their proximity to the aerodigestive tract and the high probability of aerosol generation during patient evaluation and treatment.

AIM: To provide essential guidance for Latin American multidisciplinary teams, regarding the evaluation and treatment of oropharyngeal and esophageal dysphagia, at the different levels of healthcare. The position statement was formulated for the purpose of maintaining medical service continuity, in the context of a pandemic, and minimizing the propagation and infection risks of the virus.

METHODS: Thirteen experts in swallowing disorders were summoned by the Latin American Dysphagia Society to formulate a series of clinical suggestions, based on available evidence and clinical experience, for the management of dysphagia, taking the characteristics of Latin American healthcare systems into account.

RESULTS: The position statement of the Latin American Dysphagia Society provides a series of clinical suggestions directed at the multidisciplinary teams that manage patients with oropharyngeal and esophageal dysphagia. It presents guidelines for evaluation and treatment in different contexts, from hospitalization to home care.

CONCLUSIONS: The present statement should be analyzed by each team or healthcare professional, to reduce the risk for COVID-19 infection and achieve the best therapeutic results, while at the same time, being mindful of the reality of each Latin American country.},
}

*COVID-19
*Deglutition Disorders/epidemiology/therapy
Humans
Latin America/epidemiology
Pandemics
SARS-CoV-2

@article {pmid34933373,
year = {2022},
author = {Gralnek, IM and Hassan, C and Ebigbo, A and Fuchs, A and Beilenhoff, U and Antonelli, G and Bisschops, R and Arvanitakis, M and Bhandari, P and Bretthauer, M and Kaminski, MF and Lorenzo-Zuniga, V and Rodriguez de Santiago, E and Siersema, PD and Tham, TC and Triantafyllou, K and Tringali, A and Voiosu, A and Webster, G and de Pater, M and Fehrke, B and Gazic, M and Gjergek, T and Maasen, S and Waagenes, W and Dinis-Ribeiro, M and Messmann, H},
title = {ESGE and ESGENA Position Statement on gastrointestinal endoscopy and COVID-19: Updated guidance for the era of vaccines and viral variants.},
journal = {Endoscopy},
volume = {54},
number = {2},
pages = {211-216},
doi = {10.1055/a-1700-4897},
pmid = {34933373},
issn = {1438-8812},
mesh = {*COVID-19 ; Endoscopy, Gastrointestinal ; *Gastroenterology ; Humans ; SARS-CoV-2 ; *Vaccines ; },
}

*COVID-19
Endoscopy, Gastrointestinal
*Gastroenterology
Humans
SARS-CoV-2
*Vaccines

@article {pmid34915764,
year = {2021},
author = {Wang, X and Gkrouzman, E and Andrade, DCO and Andreoli, L and Barbhaiya, M and Belmont, HM and Branch, DW and de Jesús, GR and Efthymiou, M and Ríos-Garcés, R and Gerosa, M and El Hasbani, G and Knight, J and Meroni, PL and Pazzola, G and Petri, M and Rand, J and Salmon, J and Tektonidou, M and Tincani, A and Uthman, IW and Zuily, S and Zuo, Y and Lockshin, M and Cohen, H and Erkan, D and , },
title = {COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION).},
journal = {Lupus},
volume = {30},
number = {14},
pages = {2276-2285},
pmid = {34915764},
issn = {1477-0962},
support = {R01 AR069572/AR/NIAMS NIH HHS/United States ; },
mesh = {*Antibodies, Antiphospholipid ; *Antiphospholipid Syndrome ; *COVID-19/pathology ; Humans ; *Thrombosis/virology ; },
abstract = {Coronavirus disease 2019 (COVID-19) is associated with a high rate of thrombosis. Prolonged activated partial thromboplastin times (aPTT) and antiphospholipid antibodies (aPL) are reported in COVID-19 patients. The majority of publications have not reported whether patients develop clinically relevant persistent aPL, and the clinical significance of new aPL-positivity in COVID-19 is currently unknown. However, the reports of aPL-positivity in COVID-19 raised the question whether common mechanisms exist in the pathogenesis of COVID-19 and antiphospholipid syndrome (APS). In both conditions, thrombotic microangiopathy resulting in microvascular injury and thrombosis is hypothesized to occur through multiple pathways, including endothelial damage, complement activation, and release of neutrophil extracellular traps (NETosis). APS-ACTION, an international APS research network, created a COVID-19 working group that reviewed common mechanisms, positive aPL tests in COVID-19 patients, and implications of COVID-19 infection for patients with known aPL positivity or APS, with the goals of proposing guidance for clinical management and monitoring of aPL-positive COVID-19 patients. This guidance also serves as a call and focus for clinical and basic scientific research.},
}

*Antibodies, Antiphospholipid
*Antiphospholipid Syndrome
*COVID-19/pathology
Humans
*Thrombosis/virology

@article {pmid34855691,
year = {2022},
author = {Keder, RD and Mittal, S and Stringer, K and Wallis, KE and Wallace, JE and Soares, NS},
title = {Society for Developmental & Behavioral Pediatrics Position Statement on Telehealth.},
journal = {Journal of developmental and behavioral pediatrics : JDBP},
volume = {43},
number = {1},
pages = {55-59},
doi = {10.1097/DBP.0000000000001046},
pmid = {34855691},
issn = {1536-7312},
mesh = {*COVID-19 ; Humans ; Pandemics ; *Pediatrics ; SARS-CoV-2 ; *Telemedicine ; },
abstract = {Telehealth has long held promise as a way to increase access to subspecialty care for children and families, including in developmental and behavioral pediatrics (DBP). The coronavirus disease 2019 (COVID-19) pandemic necessitated rapid uptake of telehealth to continue care delivery that was facilitated by "temporary" policy changes related to the pandemic. As a result, the field of DBP has recognized telehealth as a potential model of care for performing home-based diagnostic assessments, providing medication management follow-up, and delivering therapeutic interventions for children with neurodevelopmental disorders. Telehealth has been helpful in mitigating barriers families often face when attending in-person visits (lack of transportation and child care, missed work hours, etc) but has also highlighted additional determinants of health that need to be addressed to provide equitable access to care (broadband connectivity, device access, digital literacy, access to interpretation and sign language services, etc). Anticipating the lifting of pandemic-related emergency declaration and expiration of temporary policies around telehealth, the ability to continue to deliver DBP care by telehealth is uncertain. The purpose of this policy statement is to advocate for legislation and policies that support ongoing, equitable, home-based telehealth care for patients seen by DBP providers while ensuring equitable access to DBP in general. In addition, there is a need to recognize the benefits and challenges of telehealth versus in-person care and to identify clinical scenarios that favor 1 model of care versus the other.},
}

*COVID-19
Humans
Pandemics
*Pediatrics
SARS-CoV-2
*Telemedicine

@article {pmid34845404,
year = {2021},
author = {Curcio, A and Spaccarotella, C and Brunetti, ND and Molinari, G and Carugo, S and Basso, C and Ciccone, MM and Filardi, PP and Mancone, M and Mercuro, G and Muscoli, S and Nodari, S and Pedrinelli, R and Barillà, F and Sinagra, G and Indolfi, C},
title = {[Italian Society of Cardiology (SIC) Position paper: Technical, instrumental and standards of interpretation for electrocardiography, ambulatory electrocardiographic and blood pressure monitoring in telemedicine].},
journal = {Giornale italiano di cardiologia (2006)},
volume = {22},
number = {12},
pages = {1017-1023},
doi = {10.1714/3698.36881},
pmid = {34845404},
issn = {1972-6481},
mesh = {Blood Pressure ; Blood Pressure Monitoring, Ambulatory ; *COVID-19 ; *Cardiology ; Electrocardiography, Ambulatory ; Humans ; Pandemics ; SARS-CoV-2 ; *Telemedicine ; },
abstract = {The current COVID-19 pandemic has renewed interest in providing healthcare services based on the implementation of innovative technologies. Such strategy capillarizes the therapeutic opportunities for larger urban areas, mostly when people are living under extraordinarily difficult circumstances. Improving care delivery in cardiovascular diseases appears particularly feasible when telemedicine is pursued, especially with regard to baseline standard 12-lead electrocardiography, ambulatory electrocardiographic monitoring, and 24-hour ambulatory blood pressure monitoring. Nowadays, these first-line cardiovascular examinations are also available in health centers and pharmacies, and in recent months, there has been an increasing demand of such local services in the absence of specific rules and regulations regarding technical requirements and standards of interpretation that ensure a high quality clinical consultation.The purpose of this position paper is to provide critical requirements for the type/model of devices to be used, training dedicated to healthcare personnel, ensuring security of sensitive data, highlighting type of platforms to be used, as well as for maintaining high reporting quality and standards.},
}

Blood Pressure
Blood Pressure Monitoring, Ambulatory
*COVID-19
*Cardiology
Electrocardiography, Ambulatory
Humans
Pandemics
SARS-CoV-2
*Telemedicine

@article {pmid34841822,
year = {2021},
author = {Latif, A and Faull, C and Waring, J and Wilson, E and Anderson, C and Avery, A and Pollock, K},
title = {Managing medicines at the end of life: a position paper for health policy and practice.},
journal = {Journal of health organization and management},
volume = {35},
number = {9},
pages = {368-377},
pmid = {34841822},
issn = {1758-7247},
mesh = {*COVID-19 ; Death ; Health Policy ; Humans ; *Pandemics ; SARS-CoV-2 ; },
abstract = {PURPOSE: The impact of population ageing is significant, multifaceted and characterised by frailty and multi-morbidity. The COVID-19 pandemic has accelerated care pathways and policies promoting self-management and home-based care. One under-researched area is how patients and family caregivers manage the complexity of end-of-life therapeutic medicine regimens. In this position paper the authors bring attention to the significant strain that patients and family caregivers experience when navigating and negotiating this aspect of palliative and end-of-life care.

DESIGN/METHODOLOGY/APPROACH: Focussing on self-care and organisation of medicines in the United Kingdom (UK) context, the paper examines, builds on and extends the debate by considering the underlying policy assumptions and unintended consequences for individual patients and family care givers as they assume greater palliative and end-of-life roles and responsibilities.

FINDINGS: Policy makers and healthcare professionals often lack awareness of the significant burden and emotional work associated with managing and administering often potent high-risk medicines (i.e. opioids) in the domiciliary setting. The recent "revolution" in professional roles associated with the COVID-19 pandemic, including remote consultations and expanding community-based care, means there are opportunities for commissioners to consider offering greater support. The prospect of enhancing the community pharmacist's medicine optimisation role to further support the wider multi-disciplinary team is considered.

ORIGINALITY/VALUE: The paper takes a person-focused perspective and adopts a holistic view of medicine management. The authors argue for urgent review, reform and investment to enable and support terminally ill patients and family caregivers to more effectively manage medicines in the domiciliary setting. There are clear implications for pharmacists and these are discussed in the context of public awareness, inter-professional collaboration, organisational drivers, funding and regulation and remote care delivery.},
}

*COVID-19
Death
Health Policy
Humans
*Pandemics
SARS-CoV-2

@article {pmid34810293,
year = {2022},
author = {Bharadva, K and Bellad, RM and Tiwari, S and Somasekar, R and Phadke, M and Bodhankar, U and Bang, A and Kinikar, AA and Mallikarjuna, HB and Shah, J and Khurana, O and Gunasingh, D and Basavaraja, GV and Kumar, R and Gupta, P},
title = {Breastfeeding in Coronavirus Disease 2019 (COVID-19): Position Statement of Indian Academy of Pediatrics and Infant and Young Child Feeding Chapter.},
journal = {Indian pediatrics},
volume = {59},
number = {1},
pages = {58-62},
pmid = {34810293},
issn = {0974-7559},
mesh = {Breast Feeding ; *COVID-19 ; Child ; Female ; Humans ; Infant ; Pandemics ; *Pediatrics ; SARS-CoV-2 ; },
abstract = {JUSTIFICATION: Recent research has provided evidence for lack of transmission of SARS-CoV-2 through human milk and breastfeeding. Updating the practice guidelines will help in providing appropriate advice and support regarding breastfeeding during the coronavirus 2019 (COVID-19) pandemic.

OBJECTIVES: To provide evidence-based guidelines to help the healthcare professionals to advise optimal breastfeeding practices during the COVID-19 pandemic.

PROCESS: Formulation of key questions was done under the chairmanship of President of the IAP. It was followed by review of literature and the recommendations of other international and national professional bodies. Through Infant and Young child (IYCF) focused WhatsApp group opinion of all members was taken. The final document was prepared after the consensus and approval by all members of the committee.

RECOMMENDATIONS: The IYCF Chapter of IAP strongly recommends unabated promotion, protection and support to breastfeeding during the COVID-19 pandemic with due precautions.},
}

Breast Feeding
*COVID-19
Child
Female
Humans
Infant
Pandemics
*Pediatrics
SARS-CoV-2

@article {pmid34711104,
year = {2022},
author = {Pandian, JD and Panagos, PD and Sebastian, IA and Sampaio Silva, G and Furie, KL and Liu, L and Owolabi, MO and Caso, V and Alrukn, SA},
title = {Maintaining stroke care during the COVID-19 pandemic in lower- and middle-income countries: World Stroke Organization Position Statement endorsed by American Stroke Association and American Heart Association.},
journal = {International journal of stroke : official journal of the International Stroke Society},
volume = {17},
number = {1},
pages = {9-17},
pmid = {34711104},
issn = {1747-4949},
support = {D43 TW012030/TW/FIC NIH HHS/United States ; R01 NS107900/NS/NINDS NIH HHS/United States ; R01 NS115944/NS/NINDS NIH HHS/United States ; U54 HG007479/HG/NHGRI NIH HHS/United States ; },
mesh = {American Heart Association ; *COVID-19 ; Developing Countries ; Humans ; Pandemics ; SARS-CoV-2 ; *Stroke/epidemiology/therapy ; United States/epidemiology ; },
abstract = {For more than a year, the SARS-CoV-2 pandemic has had a devastating effect on global health. High-, low-, and middle-income countries are struggling to cope with the spread of newer mutant strains of the virus. Delivery of acute stroke care remains a priority despite the pandemic. In order to maintain the time-dependent processes required to optimize delivery of intravenous thrombolysis and endovascular therapy, most countries have reorganized infrastructure to optimize human resources and critical services. Low-and-middle income countries (LMIC) have strained medical resources at baseline and often face challenges in the delivery of stroke systems of care (SSOC). This position statement aims to produce pragmatic recommendations on methods to preserve the existing SSOC during COVID-19 in LMIC and propose best stroke practices that may be low cost but high impact and commonly shared across the world.},
}

American Heart Association
*COVID-19
Developing Countries
Humans
Pandemics
SARS-CoV-2
*Stroke/epidemiology/therapy
United States/epidemiology

@article {pmid34694269,
year = {2022},
author = {Nicastro, E and Ebel, NH and Kehar, M and Czubkowski, P and Ng, VL and Michaels, MG and Lobritto, SJ and Martinez, M and Indolfi, G},
title = {The Impact of Severe Acute Respiratory Syndrome Coronavirus Type 2 on Children With Liver Diseases: A Joint European Society for Pediatric Gastroenterology, Hepatology and Nutrition and Society of Pediatric Liver Transplantation Position Paper.},
journal = {Journal of pediatric gastroenterology and nutrition},
volume = {74},
number = {1},
pages = {159-170},
pmid = {34694269},
issn = {1536-4801},
mesh = {*COVID-19/complications ; Child ; *Gastroenterology ; Humans ; *Liver Diseases ; *Liver Transplantation ; RNA, Viral ; SARS-CoV-2 ; Systemic Inflammatory Response Syndrome ; },
abstract = {Children are seldom affected by severe forms of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV2) infection; however, the impact of comorbidities in the clinical presentation and outcome of SARS-CoV2 in children is poorly characterized including that of chronic liver disease (CLD) and those taking immunosuppressive medications for autoimmune liver disease or following liver transplantation (LT). Although not the main target organ, a spectrum of liver involvement has been described in children infected with SARS-CoV2 and those presenting with Multisystem Inflammatory Syndrome in Children (MIS-C). The Hepatology Committee of the European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the Society of Pediatric Liver Transplantation (SPLIT) present an evidence-based position paper on liver involvement in children with SARS-CoV2 infection and its impact on those with CLD as well as LT recipients. All children may exhibit acute liver injury from SARS-CoV2 infection, and those with CLD and may experience hepatic decompensation. Preventative and therapeutic measures are discussed.},
}

*COVID-19/complications
Child
*Gastroenterology
Humans
*Liver Diseases
*Liver Transplantation
RNA, Viral
SARS-CoV-2
Systemic Inflammatory Response Syndrome

@article {pmid34692391,
year = {2021},
author = {, and Ferat, LR and Forrest, R and Sehmi, K and Santos, RD and Stewart, D and Boulton, AJM and Jiménez, BY and Riley, P and Burger, D and Jones, ESW and Tomaszewski, M and Milanese, MR and Laffin, P and Jha, V and Borisch, B and Moore, M and Pinto, FJ and Piñeiro, D and Eiselé, JL and Lackland, DT and Whelton, PK and Zhang, XH and Stavdal, A and Li, D and Hobbs, R and Pandian, JD and Brainin, M and Feigin, V},
title = {Preventing the Next Pandemic: The Case for Investing in Circulatory Health - A Global Coalition for Circulatory Health Position Paper.},
journal = {Global heart},
volume = {16},
number = {1},
pages = {66},
pmid = {34692391},
issn = {2211-8179},
mesh = {Aged ; Humans ; *COVID-19 ; Global Health ; *Noncommunicable Diseases/epidemiology/prevention & control ; Pandemics/prevention & control ; SARS-CoV-2 ; },
abstract = {The Coronavirus Disease 2019 (COVID-19) has had a continuous and robust impact on world health. The resulting COVID-19 pandemic has had a devastating physical, mental and fiscal impact on the millions of people living with noncommunicable diseases (NCDs). In addition to older age, people living with CVD, stroke, obesity, diabetes, kidney disease, and hypertension are at a particularly greater risk for severe forms of COVID-19 and its consequences. Meta-analysis indicates that hypertension, diabetes, chronic kidney disease, and thrombotic complications have been observed as both the most prevalent and most dangerous co-morbidities in COVID-19 patients. And despite the nearly incalculable physical, mental, emotional, and economic toll of this pandemic, forthcoming public health figures continue to place cardiovascular disease as the number one cause of death across the globe in the year 2020. The world simply cannot wait for the next pandemic to invest in NCDs. Social determinants of health cannot be addressed only through the healthcare system, but a more holistic multisectoral approach with at its basis the Sustainable Development Goals (SDGs) is needed to truly address social and economic inequalities and build more resilient systems. Yet there is reason for hope: the 2019 UN Political Declaration on UHC provides a strong framework for building more resilient health systems, with explicit calls for investment in NCDs and references to fiscal policies that put such investment firmly within reach. By further cementing the importance of addressing circulatory health in a future Framework Convention on Emergency Preparedness, WHO Member States can take concrete steps towards a pandemic-free future. As the chief representatives of the global circulatory health community and patients, the Global Coalition for Circulatory Health calls for increased support for the healthcare workforce, global vaccine equity, embracing new models of care and digital health solutions, as well as fiscal policies on unhealthy commodities to support these investments.},
}

Aged
Humans
*COVID-19
Global Health
*Noncommunicable Diseases/epidemiology/prevention & control
Pandemics/prevention & control
SARS-CoV-2

@article {pmid34620212,
year = {2021},
author = {Venturini, E and Montagnani, C and Garazzino, S and Donà, D and Pierantoni, L and Lo Vecchio, A and Krzysztofiak, A and Nicolini, G and Bianchini, S and Galli, L and Villani, A and Gattinara, GC and , },
title = {Treatment of children with COVID-19: update of the Italian Society of Pediatric Infectious Diseases position paper.},
journal = {Italian journal of pediatrics},
volume = {47},
number = {1},
pages = {199},
pmid = {34620212},
issn = {1824-7288},
mesh = {COVID-19/epidemiology/*therapy ; Child ; *Disease Management ; Female ; Humans ; *Infectious Disease Medicine ; Italy ; Male ; *Periodicals as Topic ; Practice Guidelines as Topic ; *SARS-CoV-2 ; *Societies, Medical ; },
}

COVID-19/epidemiology/*therapy
Child
*Disease Management
Female
Humans
*Infectious Disease Medicine
Italy
Male
*Periodicals as Topic
Practice Guidelines as Topic
*SARS-CoV-2
*Societies, Medical

@article {pmid34612556,
year = {2021},
author = {Rosano, G and Jankowska, EA and Ray, R and Metra, M and Abdelhamid, M and Adamopoulos, S and Anker, SD and Bayes-Genis, A and Belenkov, Y and Gal, TB and Böhm, M and Chioncel, O and Cohen-Solal, A and Farmakis, D and Filippatos, G and González, A and Gustafsson, F and Hill, L and Jaarsma, T and Jouhra, F and Lainscak, M and Lambrinou, E and Lopatin, Y and Lund, LH and Milicic, D and Moura, B and Mullens, W and Piepoli, MF and Ponikowski, P and Rakisheva, A and Ristic, A and Savarese, G and Seferovic, P and Senni, M and Thum, T and Tocchetti, CG and Van Linthout, S and Volterrani, M and Coats, AJS},
title = {COVID-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology.},
journal = {European journal of heart failure},
volume = {23},
number = {11},
pages = {1806-1818},
pmid = {34612556},
issn = {1879-0844},
mesh = {Aged ; *COVID-19 ; COVID-19 Vaccines ; *Cardiology ; Frail Elderly ; *Heart Failure ; Humans ; *Iron Deficiencies ; SARS-CoV-2 ; Vaccination ; },
abstract = {Patients with heart failure (HF) who contract SARS-CoV-2 infection are at a higher risk of cardiovascular and non-cardiovascular morbidity and mortality. Regardless of therapeutic attempts in COVID-19, vaccination remains the most promising global approach at present for controlling this disease. There are several concerns and misconceptions regarding the clinical indications, optimal mode of delivery, safety and efficacy of COVID-19 vaccines for patients with HF. This document provides guidance to all healthcare professionals regarding the implementation of a COVID-19 vaccination scheme in patients with HF. COVID-19 vaccination is indicated in all patients with HF, including those who are immunocompromised (e.g. after heart transplantation receiving immunosuppressive therapy) and with frailty syndrome. It is preferable to vaccinate against COVID-19 patients with HF in an optimal clinical state, which would include clinical stability, adequate hydration and nutrition, optimized treatment of HF and other comorbidities (including iron deficiency), but corrective measures should not be allowed to delay vaccination. Patients with HF who have been vaccinated against COVID-19 need to continue precautionary measures, including the use of facemasks, hand hygiene and social distancing. Knowledge on strategies preventing SARS-CoV-2 infection (including the COVID-19 vaccination) should be included in the comprehensive educational programmes delivered to patients with HF.},
}

Aged
*COVID-19
COVID-19 Vaccines
*Cardiology
Frail Elderly
*Heart Failure
Humans
*Iron Deficiencies
SARS-CoV-2
Vaccination

@article {pmid34570120,
year = {2021},
author = {Di Tano, G and Di Lenarda, A and Iacoviello, M and Oliva, F and Urbinati, S and Aspromonte, N and Cipriani, M and Caldarola, P and Murrone, A and Gulizia, MM and Colivicchi, F and Gabrielli, D},
title = {[ANMCO Position paper: Use of sacubitril/valsartan in hospitalized patients with acute heart failure].},
journal = {Giornale italiano di cardiologia (2006)},
volume = {22},
number = {10},
pages = {854-860},
doi = {10.1714/3666.36517},
pmid = {34570120},
issn = {1972-6481},
mesh = {Aminobutyrates ; Angiotensin Receptor Antagonists ; Biphenyl Compounds ; *COVID-19 ; Drug Combinations ; *Heart Failure/drug therapy ; Humans ; Pandemics ; Prospective Studies ; SARS-CoV-2 ; Stroke Volume ; Tetrazoles ; Treatment Outcome ; Valsartan ; },
abstract = {Sacubitril/valsartan (S/V) has been shown to reduce the risk of cardiovascular death or heart failure hospitalization and improve symptoms in chronic heart failure with reduced ejection fraction compared to enalapril. After 7 years since the publication of the results of PARADIGM-HF, further insight has been gained with potential new indications. Two prospective randomized multicenter studies (PIONEER-HF and TRANSITION) in patients hospitalized for acute heart failure (AHF) have shown an improved clinical outcome and biomarker profile as compared to enalapril, and good tolerability, safety and feasibility of initiating in-hospital administration of S/V. Furthermore, some studies have highlighted the favorable effects of S/V in attenuating adverse myocardial remodeling, supporting an early benefit after treatment. Observational data from non-randomized studies in AHF report that in-hospital and pre-discharge prescription of evidence-based drugs associated with better survival still remains suboptimal. Additionally, the COVID-19 pandemic has also negatively impacted on outpatient activities. Therefore, hospitalization, a real crossroads in the history of heart failure, must become a management and therapeutic opportunity for our patients. The objective of this ANMCO position paper is to encourage and facilitate early S/V administration in stabilized patients during hospitalization after an AHF episode, with the aim of improving care efficiency and clinical outcome.},
}

Aminobutyrates
Angiotensin Receptor Antagonists
Biphenyl Compounds
*COVID-19
Drug Combinations
*Heart Failure/drug therapy
Humans
Pandemics
Prospective Studies
SARS-CoV-2
Stroke Volume
Tetrazoles
Treatment Outcome
Valsartan

@article {pmid34570114,
year = {2021},
author = {Bisceglia, I and Gabrielli, D and Canale, ML and Gallucci, G and Parrini, I and Turazza, FM and Russo, G and Maurea, N and Quagliariello, V and Lestuzzi, C and Oliva, S and Di Fusco, SA and Lucà, F and Tarantini, L and Trambaiolo, P and Gulizia, MM and Colivicchi, F},
title = {[ANMCO Position paper: Cardio-oncology in the COVID-19 era].},
journal = {Giornale italiano di cardiologia (2006)},
volume = {22},
number = {10},
pages = {800-825},
doi = {10.1714/3666.36511},
pmid = {34570114},
issn = {1972-6481},
mesh = {*COVID-19 ; Humans ; *Myocardial Infarction ; *Neoplasms/therapy ; Pandemics ; SARS-CoV-2 ; },
abstract = {The COVID-19 pandemic and its impact on patients with cancer and cardiovascular disease have confirmed the particular vulnerability of this population. Indeed, not only a higher risk of contracting the infection has been reported, but also an increased occurrence of a more severe course and unfavorable outcome. Beyond the direct consequences of COVID-19, the pandemic has an enormous impact on global health systems. Screening programs and non-urgent tests have been postponed; clinical trials have suffered a setback. Similarly, in the area of cardiology care, a significant decline in ST-elevation myocardial infarction accesses and an increase in cases of late presenting heart attacks with increased mortality and complication rates have been reported. Health care systems must therefore get ready to tackle the "rebound effect" that will likely show a relative increase in the short and medium term incidence of diseases such as heart failure, myocardial infarction, arrhythmias and cardio- and cerebrovascular complications. Scientific societies are taking action to provide general guidance and recommendations aimed at mitigating the unfavorable outcomes of this pandemic emergency. Cardio-oncology, as an emerging discipline, is more flexible in modulating care pathways and represents a beacon of innovation in the development of multi-specialty patient management. In the era of the COVID-19 pandemic, cardio-oncology has rapidly modified its clinical care pathways and implemented flexible monitoring protocols that include targeted use of cardiac imaging, increased use of biomarkers, and telemedicine systems. The goal of these strategic adjustments is to minimize the risk of infection for providers and patients while maintaining standards of care for the treatment of oncologic and cardiovascular diseases. The aim of this position paper is to evaluate the impact of the COVID-19 pandemic on the management of cardio-oncologic patients with the-state-of-the-art knowledge about SARS-CoV-2 and COVID-19 in order to optimize medical strategies during and after the pandemic.},
}

*COVID-19
Humans
*Myocardial Infarction
*Neoplasms/therapy
Pandemics
SARS-CoV-2

@article {pmid34561208,
year = {2021},
author = {Sánchez-Álvarez, E and Quiroga, B and de Sequera, P and , },
title = {Position statement of the Spanish Society of Nephrology on the SARS-CoV-2 vaccines.},
journal = {Nefrologia},
volume = {41},
number = {4},
pages = {412-416},
pmid = {34561208},
issn = {2013-2514},
mesh = {*COVID-19/prevention & control ; COVID-19 Vaccines ; Humans ; *Nephrology ; RNA, Messenger ; SARS-CoV-2 ; *Vaccines ; },
abstract = {Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide over the last year causing more than one million deaths. Several treatments have tried to modify the natural history of the coronavirus disease 2019 (COVID-19) but only corticosteroids have demonstrated to be effective in moderate or severe affectation. In that situation, the development of vaccines for preventing the SARS-CoV-2 infection has focused the attention of the scientific community. At present, available messenger RNA-based technology vaccines have received the approval of local and international sanitary authorities. In this position statement, the Spanish Society of Nephrology wants to state that patients with chronic kidney disease and healthcare workers are at high-risk for contagion and complications of COVID-19 so they must have priority in the vaccine administration.},
}

*COVID-19/prevention & control
COVID-19 Vaccines
Humans
*Nephrology
RNA, Messenger
SARS-CoV-2
*Vaccines

@article {pmid34532923,
year = {2022},
author = {Testino, G and Vignoli, T and Patussi, V and Allosio, P and Amendola, MF and Aricò, S and Baselice, A and Balbinot, P and Campanile, V and Fanucchi, T and Macciò, L and Meneguzzi, C and Mioni, D and Parisi, M and Renzetti, D and Rossin, R and Gandin, C and Bottaro, LC and Caio, G and Lungaro, L and Zoli, G and Scafato, E and Caputo, F},
title = {Alcohol use disorder in the COVID-19 era: Position paper of the Italian Society on Alcohol (SIA).},
journal = {Addiction biology},
volume = {27},
number = {1},
pages = {e13090},
pmid = {34532923},
issn = {1369-1600},
mesh = {Alcoholics Anonymous ; Alcoholism/epidemiology/*therapy ; Ambulatory Care/organization & administration ; COVID-19/epidemiology/*prevention & control ; COVID-19 Vaccines/therapeutic use ; *Communicable Disease Control ; Delivery of Health Care/organization & administration ; Disease Susceptibility ; Drug Interactions ; Humans ; Immunosuppression Therapy/adverse effects ; Italy/epidemiology ; Liver Cirrhosis, Alcoholic/epidemiology/therapy ; Liver Transplantation ; Recurrence ; SARS-CoV-2 ; Societies, Medical ; Telemedicine ; COVID-19 Drug Treatment ; },
abstract = {Coronavirus disease 2019 (COVID-19) first emerged in China in November 2019. Most governments have responded to the COVID-19 pandemic by imposing a lockdown. Some evidence suggests that a period of isolation might have led to a spike in alcohol misuse, and in the case of patients with alcohol use disorder (AUD), social isolation can favour lapse and relapse. The aim of our position paper is to provide specialists in the alcohol addiction field, in psychopharmacology, gastroenterology and in internal medicine, with appropriate tools to better manage patients with AUD and COVID-19,considering some important topics: (a) the susceptibility of AUD patients to infection; (b) the pharmacological interaction between medications used to treat AUD and to treat COVID-19; (c) the reorganization of the Centre for Alcohol Addiction Treatment for the management of AUD patients in the COVID-19 era (group activities, telemedicine, outpatients treatment, alcohol-related liver disease and liver transplantation, collecting samples); (d) AUD and SARS-CoV-2 vaccination. Telemedicine/telehealth will undoubtedly be useful/practical tools even though it remains at an elementary level; the contribution of the family and of caregivers in the management of AUD patients will play a significant role; the multidisciplinary intervention involving experts in the treatment of AUD with specialists in the treatment of COVID-19 disease will need implementation. Thus, the COVID-19 pandemic is rapidly leading addiction specialists towards a new governance scenario of AUD, which necessarily needs an in-depth reconsideration, focusing attention on a safe approach in combination with the efficacy of treatment.},
}

Alcoholics Anonymous
Alcoholism/epidemiology/*therapy
Ambulatory Care/organization & administration
COVID-19/epidemiology/*prevention & control
COVID-19 Vaccines/therapeutic use
*Communicable Disease Control
Delivery of Health Care/organization & administration
Disease Susceptibility
Drug Interactions
Humans
Immunosuppression Therapy/adverse effects
Italy/epidemiology
Liver Cirrhosis, Alcoholic/epidemiology/therapy
Liver Transplantation
Recurrence
SARS-CoV-2
Societies, Medical
Telemedicine
COVID-19 Drug Treatment

@article {pmid41379427,
year = {2025},
author = {Salamh, P and Dilibe-Daramola, F and Flannery, A and Pollard, C and Rocha, R and Lapidow, A and Wooten, L},
title = {Incidence and characteristics among individuals developing frozen shoulder following COVID-19 vaccine administration: A systematic review.},
journal = {Physiotherapy theory and practice},
volume = {},
number = {},
pages = {1-8},
doi = {10.1080/09593985.2025.2601894},
pmid = {41379427},
issn = {1532-5040},
abstract = {PURPOSE: Perform a systematic review to determine incidence and characteristics of vaccine administration of those developing frozen shoulder (FS) following COVID-19 vaccine administration.

METHODOLOGY: Systematic review of the literature (PROSPERO number CRD42024611140). Inclusion criteria; diagnosis of frozen shoulder, published or available in the English language and onset of frozen shoulder linked to COVID-19 vaccination. Studies were excluded if FS was linked to onset outside of vaccination and if data were not separated. Relevant studies were assessed for inclusion and selected studies were identified from PubMed, EMBASE, EBSCOhost, Cochrane Library, Web of Science and CINAHL databases. The search strategy was developed by a biomedical librarian run on August 4, 2025. Data were extracted from retained studies and underwent quality assessment using The Joanna Briggs Institute Critical Appraisal Checklist.

RESULTS: The search resulted in 1,506 studies and 9 retained for appraisal. A total of 140 individuals were identified among the retained studies with past medical history being reported in 6 of these studies identifying diabetes and hypothyroidism among the most common. Vaccine manufacturer and symptom manifestation data were reported in all retained studies. Incidence could not be determined based on available data.

CONCLUSION: In addition to known risk factors associated with vaccinations, those with comorbidities associated with the etiology of FS may also be predisposed to developing FS following COVID-19 vaccination administration. Clinicians evaluating those with suspected FS should be aware of the link between vaccinations and the development of FS. Additionally, clinicians administering COVID-19 vaccinations and boosters need to be aware of potential risk factors that may predispose individuals to developing FS following as well as possible signs and symptoms to be aware of post-vaccination.},
}

@article {pmid41379362,
year = {2025},
author = {Nazarian, E and Sinnige, JS and Bos, LDJ and Smit, MR},
title = {Advances in bedside imaging: lung ultrasound.},
journal = {Intensive care medicine experimental},
volume = {13},
number = {1},
pages = {126},
pmid = {41379362},
issn = {2197-425X},
abstract = {Lung ultrasound has become an indispensable tool in the management of acute respiratory failure, offering real-time, radiation-free bedside imaging. Its portability, repeatability, and high sensitivity for detecting pulmonary abnormalities have made it particularly valuable in critical care settings, especially during the Coronavirus disease 2019 pandemic. This narrative review explores the evolving role of lung ultrasound, examining both its established clinical applications and recent advances in artificial intelligence and imaging analysis. These developments emphasize the growing importance of lung ultrasound not only as a diagnostic tool but also as a platform for innovation, with artificial intelligence-driven approaches to further enhance its clinical utility.},
}

@article {pmid41379358,
year = {2025},
author = {Gomes, P and de Menêses, AG and Silveira, RCCP and Guerra, ENS and Dos Reis, PED and Ferreira, EB},
title = {Radiation recall dermatitis in cancer patients previously undergoing radiotherapy: a scoping review.},
journal = {Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer},
volume = {34},
number = {1},
pages = {26},
pmid = {41379358},
issn = {1433-7339},
mesh = {Humans ; *Radiodermatitis/etiology/epidemiology ; *Neoplasms/radiotherapy/drug therapy ; Antineoplastic Agents/adverse effects/administration & dosage ; Female ; Radiotherapy/adverse effects ; },
abstract = {PURPOSE: To map the evidence related to radiation recall dermatitis (RRD) in cancer patients previously treated with radiotherapy.

METHODS: A scoping review was conducted following the methodology outlined by the JBI Collaboration. The search was performed in PubMed, CINAHL, LILACS, Scopus, Web of Science Core Collection, Cochrane, and grey literature using Google Scholar and ProQuest on January 28, 2025. Studies published in any language and without restrictions on publication year were included.

RESULTS: This review incorporated 210 studies on RRD in cancer patients, with a predominance of case reports and case series (84.7%). Approximately 48% of cases were reported in breast cancer patients. Among these studies, 92 primary articles documented 201 instances of RRD. A significant association was identified with antineoplastic agents (73.6%), predominantly due to chemotherapy, with docetaxel identified as the most frequently reported agent (13.5%). The radiotherapy doses administered ranged from 8 to 65 Grays, and the time intervals between radiotherapy and the onset of the RRD-triggering agent varied widely, from hours to 40 years. This condition can cause symptoms such as erythema, dry and moist desquamation, edema, itching, pain, ulceration, necrosis, and bleeding.

CONCLUSION: RRD is a significant adverse event, particularly among women with breast cancer, most commonly associated with chemotherapy involving docetaxel and doxorubicin. COVID-19 infection and vaccination have also been reported as potential new triggers of RRD. Further research is needed to clarify the underlying mechanisms and to optimize therapeutic strategies for at-risk patients.},
}

Humans
*Radiodermatitis/etiology/epidemiology
*Neoplasms/radiotherapy/drug therapy
Antineoplastic Agents/adverse effects/administration & dosage
Female
Radiotherapy/adverse effects

@article {pmid41379341,
year = {2025},
author = {Mahdizadeh, S and Hamid, KH and Roudsari, MB and Jamil, NY and Alfarttoosi, KH and Taher, SG and Alwan, M and Jawad, M and Mushtaq, H and Soleimani, M and Tabatabaei, SN},
title = {Impact of emerging and re-emerging viral infections on periodontitis progression.},
journal = {Archives of microbiology},
volume = {208},
number = {1},
pages = {59},
pmid = {41379341},
issn = {1432-072X},
mesh = {Humans ; *Periodontitis/virology/microbiology/pathology/immunology ; *COVID-19/complications/virology ; *Virus Diseases/virology/complications ; Disease Progression ; SARS-CoV-2 ; },
abstract = {Periodontitis is a chronic inflammatory disease that progressively destroys the tooth-supporting structures, including the gums, periodontal ligament, and alveolar bone. This destruction is primarily driven not by the bacteria themselves, but by the host's dysregulated immune response to a dysbiotic subgingival biofilm. Bacterial colonization in periodontal disease (PD) triggers both innate and adaptive immune responses. Furthermore, numerous viruses-including human cytomegalovirus (HCMV), Epstein-Barr virus (EBV), and herpes simplex virus (HSV)-have been linked to periodontal disorders and contribute to the etiopathogenesis of periodontitis alongside bacteria. Since its emergence in 2020, COVID-19 has posed a significant global health threat. SARS-CoV-2 infection within the periodontium may induce local inflammation, potentially exacerbating PDs. Given that viral replication and persistence in tissues are thought to increase with the severity of inflammation, the presence of these viruses may be linked to the development and progression of periodontitis. The current study is unique in its synthesis of data on a wide spectrum of viruses associated with periodontitis. This includes common viruses (EBV, HCMV, HSV, human papillomavirus (HPV), and human immunodeficiency virus (HIV)), emerging viruses (Chikungunya, Dengue), and novel viruses such as SARS-CoV-2. By providing a comprehensive overview of viral co-infections in periodontitis, this review advocates for the development of new antiviral diagnostic and therapeutic strategies that adopt a broad, virus-centric approach. We conducted a literature search across PubMed, Google Scholar, and Web of Science using keywords and Medical Subject Headings (MeSH) terms such as "viral infection," "periodontitis," and specific virus names.},
}

Humans
*Periodontitis/virology/microbiology/pathology/immunology
*COVID-19/complications/virology
*Virus Diseases/virology/complications
Disease Progression
SARS-CoV-2

@article {pmid41379191,
year = {2025},
author = {La Scaléa, ACR and Uehara, SCDSA},
title = {Pain in Long COVID: A scoping review of clinical characteristics and patterns of manifestation.},
journal = {Revista latino-americana de enfermagem},
volume = {33},
number = {},
pages = {e4777},
doi = {10.1590/1518-8345.7836.4777},
pmid = {41379191},
issn = {1518-8345},
mesh = {Humans ; *COVID-19/complications ; Female ; *Pain/etiology/diagnosis/epidemiology ; Male ; Pain Measurement ; SARS-CoV-2 ; },
abstract = {to map the available scientific evidence on the clinical characteristics and patterns of pain manifestation (location, frequency, duration, intensity, and quality) in individuals with Long COVID. a scoping review of publications from March 2020 to June 2024, indexed across four databases. Study selection was conducted by two independent, blinded reviewers. Data were extracted using a standardized instrument and analyzed descriptively. nineteen studies were included, indicating that pain affects individuals across all age groups, with higher prevalence among women, primarily involving the head, neck, shoulder, lower back, and hip. Pain frequency ranged from daily to monthly episodes, with duration exceeding one year in some cases. Intensity varied from mild to severe, and pain characteristics were diverse, with descriptors including burning, pressure, colicky, and throbbing pain. the clinical characteristics and patterns of pain manifestation in Long COVID are diverse. However, there is a paucity of studies providing detailed analyses of pain features and the influence of individual variables. These findings should guide future research and clinical practice toward a more comprehensive and contextualized assessment of pain in Long COVID.},
}

Humans
*COVID-19/complications
Female
*Pain/etiology/diagnosis/epidemiology
Male
Pain Measurement
SARS-CoV-2

@article {pmid41378159,
year = {2025},
author = {Mahamadou, D and Abdoul-Aziz, AB and Moustapha, LM and Alkassoum, I and Fils, SA and Hamsatou, B and Bachir, G and Abdourahmane, Y and Farouk, M and Lagare, A and Eric, A and Issifou, D and Hassane, N and Habibatou, I and Eholié, SP},
title = {Resurgence of epidemics in Zinder: effect of the decrease in vaccination coverage and the impacts of climate change.},
journal = {IJID regions},
volume = {17},
number = {},
pages = {100781},
pmid = {41378159},
issn = {2772-7076},
abstract = {OBJECTIVES: Several epidemic outbreaks have affected the Zinder region. These include diseases targeted by the expanded immunization program and other emerging diseases. This study aimed to analyze these epidemics.

METHODS: This is documentary research of the epidemics of meningitis, measles, cholera, COVID-19, and diphtheria, which occurred in the Zinder region from 2015 to 2023, as well as their determinants. The data collection is made from the linear list of notifiable diseases of the Regional Directorate of Health and Public Hygiene of Zinder, associated with literature review on the determinants of the appearance of these epidemics.

RESULTS: The number of meningitis cases has gradually increased in Zinder from 2019 to 2024. A total of 5019 cases were registered during these epidemics, with a mortality rate of 6.31%. Five measles epidemics have been recorded since 2015. A total of 13,887 cases were notified during these epidemics, with a mortality rate of 0.30%. Three cholera epidemics occurred: in 2021, in 2022, and in 2024. During these epidemics, 884 cases were recorded, with 24 deaths or a lethality of 2.71%. The COVID-19 epidemic occurred in 2020, with 364 cases, including 17 deaths, i.e. a mortality rate of 4.67%. Since 2022, the region has been facing a diphtheria epidemic. A total of 3310 cases has been reported, with 173 deaths. The causes of these epidemics are multifaceted; they involve the decline in vaccination coverage, migration, insecurity, the COVID-19 pandemic, and climate change.

CONCLUSIONS: The impact of epidemics on the health of the population and the socio-economic development of regions implies a greater mastery of the root causes mentioned in this study.},
}

@article {pmid41378119,
year = {2025},
author = {Shepherd, J and Leake, MC},
title = {Invention, innovation, and commercialisation in British biophysics.},
journal = {Biophysical reviews},
volume = {17},
number = {4},
pages = {1143-1156},
pmid = {41378119},
issn = {1867-2450},
abstract = {British biophysics has a tradition of scientific invention and innovation, resulting in new technologies transforming biological insight, such as rapid DNA sequencing, super-resolution and label-free microscopy, high-throughput and single-molecule bio-sensing, and bio-inspired synthetic materials. Some advances were established through democratised platforms and many have biomedical success, a key example involving the SARS-CoV-2 spike protein during the COVID-19 pandemic. Here, three UK labs made crucial contributions revealing how the spike protein targets human cells and how therapies of vaccines and neutralising nanobodies work, enabled largely through biophysical innovations of cryo-electron microscopy. Here, we discuss leading-edge innovations which resulted from discovery-led British "Physics of Life" research (capturing blends of physical-life sciences research in the UK including biophysics and biological physics) and have matured into wide-reaching sustainable commercial ventures enabling translational impact. We describe the biophysical science which led to these academic spinouts, presenting the scientific questions that were addressed through innovating new techniques and approaches. We consider these examples through the lens of opportunities and challenges for academic biophysics research in partnership with British industry. We highlight how commercial breakthroughs have emerged organically from fundamental research rather than from technology-first approaches but also discuss lessons to learn from past failures. Finally, we propose recommendations concerning future resourcing and structuring of UK biophysics research and the training and support of its researchers to ensure that UK plc punches above its weight in biophysics innovation and a need to educate the policymakers and public that an absence of basic science impoverishes innovation.},
}

@article {pmid41378112,
year = {2025},
author = {Mijangos, LRR and Harding, SE and Darton, NJ},
title = {Developing high-concentration monoclonal antibody formulations for subcutaneous administration to improve patient treatment.},
journal = {Biophysical reviews},
volume = {17},
number = {4},
pages = {1013-1031},
pmid = {41378112},
issn = {1867-2450},
abstract = {The transition of immunotherapy administration from intravenous infusion to subcutaneous (SC) administration of monoclonal antibody formulations for oncology patients has garnered significant interest. SC administration offers multiple benefits, including potential for at-home administration, enhanced patient compliance, reduced hospital congestion, lowered health care costs, and improved sustainability by reducing drug wastage and minimizing environmental impact. However, for many biologics, the shift to SC administration requires the development of high-concentration monoclonal antibody products (HCmAP) due to the need for large dose volumes. Here we explore the impact of the COVID-19 pandemic on immunotherapy administration and the imperative of adopting SC administration. We discuss challenges encountered throughout the manufacturing, shipping, storage, and delivery of HCmAP. A central hurdle identified involves the biophysical instability and the large increase in viscosity of these biologics due to increased antibody concentration. Further complications can arise from "non-ideality" effects through molecular crowding or co-exclusion effects (macromolecules blocking the free movement in solution of other macromolecules) and elevated macromolecular interactions. For reducing the viscosity for a given concentration of antibody, the main excipients reported are salts and amino acids, with Arg-HCl demonstrating particularly improved formulation viscosity in an HCmAP. However, excipients with viscosity-lowering effects can also impact protein stability. The journey to discover suitable excipient strategies remains ongoing, combined with emerging approaches such as molecular engineering and computational techniques, with the ultimate aim of facilitating the successful integration of SC administration for economic savings, environmental sustainability, and social equity.},
}

@article {pmid41377933,
year = {2025},
author = {Yang, B and Liu, J and Li, Y and Liu, X},
title = {mRNA Cancer Vaccines: From Pandemic Paradigm to Personalized Oncology Therapeutics.},
journal = {Cancer innovation},
volume = {4},
number = {6},
pages = {e70041},
pmid = {41377933},
issn = {2770-9183},
abstract = {The groundbreaking success of messenger RNA (mRNA) vaccines during the COVID-19 pandemic has significantly accelerated their application in oncology. This review comprehensively synthesizes the recent advancements in mRNA cancer vaccine development, emphasizing three critical domains: mechanistic innovations, clinical translation, and ongoing challenges. Technologically, advancements in nucleotide modification, lipid nanoparticle (LNP) delivery systems, and AI-driven neoantigen selection have significantly improved vaccine stability, immunogenicity, and personalization. Clinically, more than 150 trials have demonstrated the synergistic efficacy of mRNA vaccines (e.g., mRNA-4157/V940, BNT122) in combination with immune checkpoint inhibitors (ICIs), particularly in melanoma, with Phase III trials currently underway. Individualized neoantigen vaccines targeting patient-specific mutations have shown unprecedented response rates (> 50% in certain cohorts), while shared-antigen vaccines are progressing for high-incidence cancers. However, several critical challenges remain: (1) overcoming immunosuppressive tumor microenvironments (TME), (2) addressing systemic toxicities and LNP-related limitations, (3) scaling up cost-effective personalized manufacturing, and (4) optimizing targeted delivery. Future research directions encompass self-amplifying mRNA constructs, novel biomaterial vectors, neoadjuvant applications, and multi-omics integration for next-generation vaccine development. With rapid industrialization and evolving regulatory frameworks, mRNA vaccines are well-positioned to revolutionize precision cancer immunotherapy despite persistent translational barriers.},
}

@article {pmid41377469,
year = {2025},
author = {Ali, A and Shariq, K and Ashok Kumar, K and Zakai, A and Mumtaz, K and Ali, Z and Akmal, M and Kailash, SJ},
title = {Analyzing global research trends in hepatology during Coronavirus Disease 2019: a bibliometric analysis.},
journal = {Annals of medicine and surgery (2012)},
volume = {87},
number = {12},
pages = {8376-8384},
pmid = {41377469},
issn = {2049-0801},
abstract = {OBJECTIVE: Analyzing global hepatology trends during Coronavirus Disease 2019 (COVID-19) to accelerate effective treatments and protocols for researchers and healthcare systems.

METHODS: The related papers to COVID-19 and hepatology were extracted from 2019 to 2023. The articles were ranked according to the number of citations and a final list of top 101 most-cited articles were shortlisted. Analysis was carried out on the following: total citation count, publication year, journal name and its Impact factor, gender and their H-index, country of origin, funding information, and content of the articles. Citations per year and citations per author were calculated for all articles.

RESULTS: Between 2019 and 2023, the top 101 cited articles covered various topics. The highest number were published in 2021 (n = 42), with the American Journal of Transplantation contributing the most (n = 23). The University of Pennsylvania had the most influential presence (n = 5). These articles came from 44 countries where the US ranked first with 35 articles. There were a total of 160 authors involved, with each paper having a median and mean of 6 and 7.3 authors, respectively. The articles were categorized into nine main topics, with therapeutic intervention being the most common (n = 26) followed by pathophysiology (n = 20). Males outnumbered females as first and senior authors. A majority (n = 55) received funding, and most (n = 81) did not declare conflicts of interest.

CONCLUSION: Top articles in our analysis focused on liver transplantation, pathophysiology, and healthcare management. It can aid researchers in assessing the effectiveness of different treatment modalities for hepatic impairment in COVID-19 patients.},
}

@article {pmid41377081,
year = {2025},
author = {Lin, L and Talib, MBA},
title = {Exploring the relationship between domain-specific self-efficacy and motivation among university students: a systematic review (2019-2024).},
journal = {Frontiers in psychology},
volume = {16},
number = {},
pages = {1702507},
pmid = {41377081},
issn = {1664-1078},
abstract = {The interplay between domain-specific self-efficacy and motivation in higher education has garnered significant attention, particularly in the context of challenges such as the COVID-19 pandemic that have profoundly altered the educational landscape. This study provides a systematic review of the literature on the relationship between domain-specific self-efficacy and motivation among university students, adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. From an initial pool of 5,890 articles sourced from the Education Resources Information Centre (ERIC), Scopus, and Web of Science (WoS) databases, 31 studies published between 2019 and 2024 were analyzed. Our findings underscore a predominantly positive correlation between domain-specific self-efficacy and motivation. Higher levels of self-efficacy are consistently linked to increased motivation, suggesting that enhancing self-efficacy could be a crucial strategy for boosting student motivation and, thus, academic success. Notably, many studies focus on Asian regions, highlighting both the universality and cultural specificity of these findings. However, the presence of an outlier study that found no significant relationship between self-efficacy and motivation indicates the complexity of these constructs and the potential impact of situational factors, warranting further investigation. Additionally, this review reveals a growing academic interest in self-efficacy and motivation, particularly within social sciences and education. This trend underscores the importance of a multidisciplinary approach to understanding the intricate dynamics between self-efficacy and motivation. The documented rise in research attention reflects a growing recognition of the critical role that self-efficacy and motivation play in student learning outcomes. In conclusion, this systematic review not only highlights the significant positive impact of domain-specific self-efficacy on student motivation but also calls for more nuanced studies. Future research should explore under-represented contexts and examine the broader implications of these findings across diverse educational and cultural settings.},
}

@article {pmid41376972,
year = {2025},
author = {Soto-Feijóo, R and Landín, E and Martínez-Martínez, H and Carreiras, M and Fanego, A and Ferreiro, L and Rodríguez-Núñez, N and Toubes, ME and Valdés, L},
title = {Analyzing pleural fluid attributes in SARS-CoV-2 infection: a systematic review.},
journal = {Journal of thoracic disease},
volume = {17},
number = {11},
pages = {10510-10518},
pmid = {41376972},
issn = {2072-1439},
abstract = {BACKGROUND: The characteristics of pleural fluid (PF) in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are poorly understood. During the pandemic, several cases of pleural effusion (PE) have been reported, but no clear conclusions have been reached regarding the features of this fluid. This systematic review aimed to analyze and summarize the available evidence on PF attributes in patients with SARS-CoV-2 infection.

METHODS: Systematic literature search using the PRISMA methodology of studies describing PF characteristics of SARS-CoV-2 patients and treatment of PE.

RESULTS: Eighteen articles (32 patients and 37 PF samples) were included. Median age was 61 years (range, 25-81 years), male/female ratio 5.4:1. PE was predominantly unilateral (71.4%), with no distinction between one side and the other; it usually extended over 2/3 of the hemithorax (50%) and its appearance was variable [serous (50%), hematic or serohematic (28.1%) and purulent (21.9%)]. PF was exudative in 88.9% of cases, but with PF protein and PF/serum protein ratio values less than 3 g/dL and 0.5 in 36.7% and 54.5%, respectively. The pH and glucose values were less than 7.20 and 60 mg/dL in 28.6% and 24% of cases, respectively. The percentage of neutrophils (≥50%) was higher than that of lymphocytes/monocytes [12/26 (46.2%) vs. 7/26 (26.9%), respectively]. Polymerase chain reaction (PCR) on PF was positive for SARS-CoV-2 in 6/23 cases (26.1%) and for other pathogens in 8 (5 bacteria and 3 fungi). Almost all patients underwent thoracentesis and the medical treatment received by the cases with positive PCR for SARS-CoV-2 on PF varied. Patient follow-up was provided in 25 cases and 10 cases died (40%).

CONCLUSIONS: PE from coronavirus disease 2019 (COVID-19) infection is more frequent among males aged 50-80 years, generally unilateral and large. Its appearance is variable, with features of lactate dehydrogenase (LDH)-discordant exudate, usually predominantly neutrophilic, with treatment like that of any other PE. PE from COVID-19 infection is a poor prognostic sign and associated with worse mortality.},
}